Document:

<PAGE>

                           JOINT DEVELOPMENT, LICENSE
                              AND SUPPLY AGREEMENT

     THIS JOINT DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT (this "Agreement"),
dated as of September 10, 1998, is entered into by and between Inspire
Pharmaceuticals, Inc., a corporation organized and existing under the laws of
the State of Delaware, having offices located at 4222 Emperor Boulevard, Suite
470, Durham, North Carolina 27703, USA ("Inspire"), and Kissei Pharmaceutical
Co., Ltd., a corporation organized under the laws of Japan, having offices
located at 19-48, Yoshino, Matsumoto-City, Nagano-Prefecture,  399-8710, Japan
("Kissei").

                                 PRELIMINARY STATEMENTS
                                 ----------------------

     A.  Inspire owns, and/or has exclusive rights to, the Patents and Know-How
in existence as of the Effective Date relating to the Compound.  In addition,
Inspire has the expertise necessary to coordinate the worldwide development and
manufacture of the Product.

     B.  Kissei has the personnel, facilities and expertise necessary for the
development and commercialization of the Product in the Territory.

     C.  The Parties wish to collaborate to develop, commercialize and market
the Product, upon the terms and conditions set forth in this Agreement.  In
connection therewith, Kissei desires to obtain, and Inspire desires to grant to
Kissei, an exclusive license under the Licensed Technology with respect to the
development and commercialization of the Product in the Territory for
applications in the Field, subject to Inspire's right to manufacture and supply
Finished Product and Delivery Systems for Kissei, all on the terms and
conditions set forth below.

     D.  Simultaneously with the execution of this Agreement, the Parties are
entering in that certain Stock Purchase Agreement (the "Stock Purchase
Agreement") and documents ancillary thereto, all dated of even date herewith,
pursuant to which Kissei is purchasing shares of Series C Preferred Stock of
Inspire.

     NOW, THEREFORE, in consideration of the foregoing Preliminary Statements
and the mutual agreements and covenants set forth herein, the Parties hereby
agree as follows:

1.   DEFINITIONS.

     As used in this Agreement, the following terms shall have the meanings set
forth in this Section 1 unless context dictates otherwise:

                                       1
<PAGE>

     1.1  "Affiliate," with respect to any Party, shall mean any entity
controlling, controlled by, or under common control with, such Party.  For these
purposes, "control" shall refer to (i) the possession, directly or indirectly,
of the power to direct the management or policies of an entity, whether through
the ownership of voting securities, by contract or otherwise, or (ii) the
ownership, directly or indirectly, of at least 50% of the voting securities or
other ownership interest of an entity.

     1.2  "Annual Development Plan" shall have the meaning assigned to such term
in Section 4.1(a).

     1.3  "Cassette" shall mean a disposable self-contained unit to be filled
with a quantity of Formulated Material sufficient to provide the number of doses
as approved by the Joint Development Committee pursuant to Section 3.2(f) (e.g.,
sufficient for dosing for one week).

     1.4  "cGMP" shall mean current Good Manufacturing Practice as defined in
Parts 210 and 211 of Title 21 of the Code of Federal Regulations, as may be
amended from time to time, or any successor thereto.

     1.5  "Compound" shall mean the chemical compound designated as INS365,
whose chemical name is P1, P4-Di(uridine 5'-tetraphosphate), and all sodium
salts thereof.

     1.6  "Compound Specifications" shall mean the specifications for the
Compound approved by the Joint Development Committee in consideration of the
regulatory requirements in the Territory, as may be amended from time to time.

     1.7  "Confidential Information" shall have the meaning assigned to such
term in Section 10.4.

     1.8  "Cost of Compound" shall mean Inspire's fully burdened costs
associated with the manufacture of the Compound, as determined pursuant to
Exhibit A.

     1.9  "Cost of Delivery Systems" shall mean Inspire's fully burdened costs
associated with the manufacture of the Delivery System, as determined pursuant
to Exhibit A.

     1.10  "Cost of Finished Product" shall mean Inspire's fully burdened costs
associated with the manufacture of the Finished Product, including without
limitation, the Cost of Formulated Material and the costs associated with
assembly of the Finished Product, as determined pursuant to Exhibit A.

     1.11  "Cost of Formulated Material" shall mean Inspire's fully burdened
costs associated with the manufacture of the Formulated Material, as determined
pursuant to Exhibit A.

                                      -2-
<PAGE>

     1.12  "Delivery System" shall mean the novel delivery system designed to
deliver Formulated Material contained within a Cassette to the lungs via
inhalation and to be reusable for at least one year, as approved by the Joint
Development Committee pursuant to Section 3.2(f).

     1.13  "Delivery System Specifications" shall mean the specifications for
the Delivery System approved by the Joint Development Committee in consideration
of the regulatory requirements in the Territory, as may be amended from time to
time.

     1.14  "Development Coordinator/Liaison" shall have the meaning assigned to
such term in Section 4.4(a).

     1.15  "Effective Date" shall mean the date of this Agreement.

     1.16  "Executive Officers" shall have the meaning assigned to such term in
Section 3.4(b).

     1.17  "Field" shall mean the treatment (but not the diagnosis) of
respiratory diseases in humans, excluding otitis media and sinusitis.

     1.18  "Finished Product" shall mean the Formulated Material: (i) loaded
into a Cassette, for use with a Delivery System, or (ii) contained in a
vial/nebule for use with standard nebulizers.

     1.19  "Finished Product Specifications" shall mean the specifications for
the Finished Product approved by the Joint Development Committee in
consideration of the regulatory requirements in the Territory, and such other
packaging and labeling specifications as are agreed upon by the Joint
Development Committee or the Parties, as the case may be, for the Finished
Product, as may be amended from time to time.

     1.20  "First Commercial Sale" shall mean, with respect to any Product, the
first sale for use or consumption by the general public of such Product in the
Territory after all required NDA Approvals have been granted, or, if such sale
is otherwise permitted, by the Regulatory Authority in the Territory.

     1.21  "Formulated Material" shall mean any inhalation formulation of any
product containing the Compound as an active ingredient.

     1.22  "Formulated Material Specifications" shall mean the specifications
for the Formulated Material approved by the Joint Development Committee in
consideration of the regulatory requirements in the Territory, as may be amended
from time to time.

     1.23   "FTE" shall mean a full-time equivalent employee of Inspire assigned
to conduct  coordination/liaison activities pursuant to Section 4.4, including
scientists, professionals or the like, but excluding non-technical, non-
professional personnel such as secretarial staff.  As used herein,

                                      -3-
<PAGE>

a "full-time equivalent" shall mean a full-time person, or in the case of less
than a full- time dedicated person, a full-time, equivalent person year, based
upon a total of 1,880 hours per year of work related to such activities.

     1.24  "Improved Analog" shall mean any dinucleotide P2Y2 receptor agonist
which has utility as an inhalation product for use in the Field.

     1.25  "IND" shall mean any filing made with the Regulatory Authority in the
Territory for initiating clinical trials in the Territory with respect to the
Product.

     1.26  "Invention" shall mean any new or useful process, manufacture,
compound or composition of matter relating to the Compound or the Product
(including, without limitation, the formulation, delivery or use thereof),
whether patentable or unpatentable, or any improvement thereof, that is
conceived or first reduced to practice or demonstrated to have utility during
the term of, and in connection with, the Joint Development Program.

     1.27  "Joint Development Committee" shall have the meaning assigned to such
term in Section 3.1.

     1.28  "Joint Development Program" shall mean the joint development program
with respect to the Product conducted by Kissei in collaboration with Inspire
pursuant to Section 4.

     1.29  "Know-how" shall mean any and all Inventions, improvements,
discoveries, claims, formulae, processes, trade secrets, technologies and know-
how (including confidential data and Confidential Information) which is
generated, owned or controlled by Inspire at any time before or during the term
of this Agreement relating to, derived from or useful for the use or sale of the
Compound or the Product, including, without limitation, synthesis, preparation,
recovery and purification processes and techniques, control methods and assays,
chemical data, toxicological and pharmacological data and techniques, clinical
data, medical uses, product forms and product formulations and specifications.

     1.30  "Licensed Claim" shall mean any claim of any Patent that relates to
and is necessary for the use and sale of the Compound or the Product, which
claim has not been held invalid or unenforceable by decision of a court or other
governmental agency of competent jurisdiction, unappealable or unappealed within
the time allowed for appeal, and which is not admitted to be invalid through
disclaimer or otherwise not admitted by Inspire to be invalid.

     1.31  "Licensed Technology" shall mean the Licensed Claims and Know-how,
collectively.

     1.32  "Manufacturing Coordinator/Liaison" shall have the meaning assigned
to such term in Section 4.4(b).

                                      -4-
<PAGE>

     1.33   "Manufacturing Standards" shall mean, with respect to the Finished
Product and Delivery System, cGMP and such additional manufacturing
specifications or standards as may be established by mutual agreement of the
Parties from time to time.

     1.34  "NDA" shall mean any filing of a New Drug Application made with the
Regulatory Authority in the Territory for NDA Approval with respect to the
Product.

     1.35  "NDA Approval" shall mean approval of the NDA for the Product filed
in the Territory, including pricing or reimbursement, where applicable, by the
Regulatory Authority in the Territory.

     1.36  "Net Sales" shall mean, with respect to the Product, the gross amount
invoiced for the Product by Kissei, its Affiliates and Sublicensees, if any, in
arm's length sales to Third Parties, commencing with the First Commercial Sale
of the Product, less deductions for: (i) trade, quantity and/or cash discounts,
allowances and rebates actually allowed or given; (ii) freight, postage,
shipping insurance and other transportation expenses (if separately identified
in such invoice); (iii) credits or refunds actually allowed for rejections,
defects or recalls of such Product, outdated or returned Product, or because of
rebates or retroactive price reductions; and (iv) sales, value-added, excise
taxes, tariffs and duties, and other taxes directly related to the sale, to the
extent that such items are included in the gross invoice price (but not
including taxes assessed against the income derived from such sale).  Such
amounts shall be determined from the books and records maintained by Kissei, its
Affiliates or Sublicensees, as applicable.

     1.37  "Party" shall mean Inspire or Kissei and, when used in the plural,
shall mean Inspire and Kissei.

     1.38  "Patents" shall mean the patents set forth on Exhibit B, and any
other patents or patent applications in the Territory owned or controlled by
Inspire during the term of this Agreement that relate to the Compound or the
Product, together with any patents that may issue therefor in the Territory,
including any and all extensions, renewals, continuations, continuations-in-
part, divisions, patents-of-additions, reissues, supplementary protection
certificates or foreign counterparts of any of the foregoing.

     1.39  "Product" shall mean any system which consists of Finished Product
and the Delivery System or Finished Product for use with standard nebulizers,
for use in the Field, the manufacture, use or sale of which either is: (i) based
upon, derived from or related to any of the Know-how; and/or (ii) covered by one
or more Licensed Claims and, but for this Agreement, would constitute an
infringement (whether directly, contributorily or by inducement) thereof.

     1.40  "Regulatory Authority" shall mean the authority(ies) in the Territory
with responsibility for granting regulatory approval for the marketing and sale
of the Product in the Territory, and any successor(s) thereto.

                                      -5-
<PAGE>

     1.41 "Specifications" shall mean the Compound Specifications, the
Formulated Material Specifications, Finished Product Specifications or the
Delivery System Specifications, either respectively or collectively, as context
may dictate.

     1.42  "Stock Purchase Agreement" shall have the meaning assigned to such
term in the Preliminary Statements.

     1.43  "Strategic Partners" shall have the meaning assigned to such term in
Section 4.4(a).

     1.44  "Sublicensee" shall mean a Third Party to which Kissei has granted a
sublicense to develop, use or sell the Product in the Territory, or who acts as
a distributor of Kissei for the resale of any Product to the trade in the
Territory, pursuant to Section 5.3.

     1.45  "Supplied Goods" shall have the meaning assigned to such term in
Section 8.1.

     1.46  "Supply Agreement" shall have the meaning assigned to such term in
Section 8.1.

     1.47  "Territory" shall mean Japan.

     1.48  "Testing Methods" shall have the meaning assigned to such term in
Section 5(c) of Exhibit D.

     1.49   "Third Party" shall mean any person who or which is neither a Party
nor an Affiliate of a Party.

     1.50  "Third Party Manufacturer" shall have the meaning assigned to such
term in Section 7(a) of Exhibit D.

     1.51  "Transfer Price" shall have the meaning assigned to such term in
Section 6.4.

     1.52  [CONFIDENTIAL TREATMENT REQUESTED].

2.   REPRESENTATIONS AND WARRANTIES.

     2.1  Representations and Warranties of Both Parties.    Each Party
represents and warrants to the other Party, as of the Effective Date, that:

                                      -6-
<PAGE>

          (a) such Party is duly organized and validly existing under the laws
of the jurisdiction of its incorporation and has full corporate power and
authority to enter into this Agreement and to carry out the provisions hereof;

          (b) such Party is free to enter into this Agreement;

          (c) in so doing, such Party will not violate any other agreement to
which it is a party;

          (d) such Party has taken all corporate action necessary to authorize
the execution and delivery of this Agreement and the performance of its
obligations under this Agreement; and

          (e) no person or entity has or will have, as a result of the
transactions contemplated by this Agreement, any right, interest or valid claim
against or upon such Party for any commission, fee or other compensation as a
finder or broker because of any act or omission by such Party or any of its
agents.

     2.2  Representations and Warranties of Inspire.    Inspire represents and
warrants to Kissei, as of the Effective Date, that:

          (a) Inspire is the owner of, or has exclusive rights to, all of the
Patents in existence on the Effective Date, and has the exclusive right to grant
the licenses granted under this Agreement therefor;

          (b) to the best of Inspire's knowledge, Inspire has exclusive rights
to all of the Know-how in existence on the Effective Date and the exclusive
right to grant licenses with respect thereto; and

          (c) Inspire has not entered into any agreement with any Third Party
which is in conflict with the rights granted to Kissei pursuant to this
Agreement.

     2.3  Representations and Warranties of Kissei.    Kissei represents and
warrants to Inspire, as of the Effective Date, that:

          (a) Kissei has the facilities, personnel and experience sufficient in
quantity and quality to perform its obligations under this Agreement;

          (b) All of the personnel assigned to perform such obligations shall be
qualified and properly trained; and

          (c) Kissei shall perform such obligations in a manner commensurate
with professional standards generally applicable in its industry.

                                      -7-
<PAGE>

3.   JOINT DEVELOPMENT COMMITTEE.

     3.1  Members; Officers.    The Parties shall establish a joint development
committee (the "Joint Development Committee"), which shall consist of six
members, three members from each Party.  At least one member from each Party
must be a clinical development professional.  The initial members of the Joint
Development Committee are set forth on Exhibit C.  Members of the Joint
Development Committee may be represented at any meeting by a designee appointed
by such member for such meeting.  The chairperson and secretary of the Joint
Development Committee shall serve coterminous one-year terms, each commencing on
the Effective Date or an anniversary thereof, as the case may be.  The right to
name the chairperson and the secretary of the Joint Development Committee shall
alternate between the Parties, and each chairperson and secretary shall be named
no later than 10 days after the commencement of his or her term.  The initial
chairperson shall be selected by Kissei and is designated on Exhibit C.  The
initial secretary shall be selected by Inspire and is designated on Exhibit C.
Each Party shall be free to change its members, on prior written notice to the
other Party.  Each Party may, in its discretion, invite non-member
representatives of such Party to attend meetings of the Joint Development
Committee, provided that the other Party approves such Party's invitee(s) in
advance.

     3.2  Responsibilities.    Subject to the other terms of this Agreement, the
Joint Development Committee shall oversee the development of the Product
pursuant to this Agreement, from the commencement of any development efforts
through the date on which all NDA Approvals in the Territory for the Product
actively being sought have been obtained.  After all such NDA Approvals have
been obtained, the Parties shall continue to collaborate in complying with all
regulatory requirements of maintaining such NDA Approvals (including post-
marketing surveillance and adverse event reporting).  Without limiting the
generality of the foregoing, the Joint Development Committee shall:

          (a) plan, supervise and coordinate the development of the Product
under this Agreement;

          (b) commencing on the Effective Date, discuss and prepare an Annual
Development Plan for the first year of the term of the Joint Development Program
and, not later than 90 days after the Effective Date, finalize an Annual
Development Plan for the first year of the term of the Joint Development
Program;

          (c) not later than three months prior to each anniversary of the
Effective Date during the term of the Joint Development Program, discuss and
prepare an Annual Development Plan, and, prior to each anniversary of the
Effective Date during the term of the Joint Development Program, finalize an
Annual Development Plan for the next year of the term of the Joint Development
Program;

                                      -8-
<PAGE>

          (d) determine whether to approve proposed amendments or modifications
to any Annual Development Plan;

          (e) review and determine whether to approve clinical study protocols,
the selection of clinical investigators, clinical study write-ups, regulatory
submissions, NDAs and the like relating to the Joint Development Program;

          (f) review and determine whether to approve the final design of the
Cassette and the Delivery System;

          (g) evaluate data from the Joint Development Program;

          (h) review all proposed publications and presentations of the Parties
pursuant to Section 10.2;

          (i) review all studies relating to the Product and any other studies
proposed to be performed in connection with the registration process for the
Product under this Agreement;

          (j) allocate responsibilities between the Parties, coordinate the
activities of the Parties, and review and evaluate progress, all under the Joint
Development Program, provided that the Joint Development Committee shall not
have authority to make any determination that either Party is in breach of its
obligations under the Joint Development Program;

          (k) determine, review and amend, from time to time, the
Specifications;

          (l) provide a mechanism for the exchange of information between the
Parties with regard to Know-how and Inventions;

          (m) resolve disputes between the Parties with respect to the
foregoing; and

          (n) have such other responsibilities as may be assigned to the Joint
Development Committee pursuant to this Agreement or as may be mutually agreed
upon by the Parties from time to time.

     3.3  Meetings.    During the term of the Joint Development Program and the
12-month period thereafter, the Joint Development Committee shall meet at least
twice during every calendar year, and more frequently as the Parties deem
appropriate, on such dates, and at such places and times, as the Parties shall
agree.  During each calendar year during the term of the Joint Development
Program and the 12-month period thereafter, meetings of the Joint Development
Committee shall be held in Japan, North Carolina or such other place as the
Parties may agree.  Thereafter, during the remainder of the term of this
Agreement, the Joint Development Committee shall meet on an as needed basis on
such dates, and at such places and times, as the Parties shall agree. The
chairperson

                                      -9-
<PAGE>

shall, if practicable, send notice of all meetings to all members of the Joint
Development Committee no less than 20 days before the date of each meeting.  The
Joint Development Committee may also convene or be polled or consulted from time
to time by means of telecommunications, video conferences or correspondence, as
deemed necessary or appropriate; provided, however, that the Joint Development
Committee must meet in person at least twice every calendar year during the term
of the Joint Development Program and the 12-month period thereafter.

     3.4  Decisions.

          (a) The Joint Development Committee may make decisions with respect to
any subject matter that is subject to the Joint Development Committee's
decision-making authority. All decisions of the Joint Development Committee
shall be made by consensus of the members (or their designees) present at any
meeting.

          (b) In the event that consensus cannot be reached by the Joint
Development Committee after good faith discussions with respect to a matter that
is subject to its decision-making authority, the matter shall be referred for
further review and resolution to the Vice Chairman of the Board, currently Dr.
David Drutz, at Inspire, or such other similar position designated by Inspire
from time to time, and the Managing Director, R&D, currently Dr. Masanori
Iwadare, at Kissei, or such other similar position designated by Kissei from
time to time (such officers collectively, the "Executive Officers").  The
Executive Officers shall use reasonable efforts to resolve the matter within 30
days after the matter is referred to them.

     3.5  Minutes.    Promptly after each Joint Development Committee meeting,
the chairperson or the secretary of Inspire shall prepare  and distribute to all
members of the Joint Development Committee draft minutes of the meeting within
10 days after the meeting.  Such minutes shall provide a description, in
reasonable detail, of the discussions had at the meeting and a list of any
actions, decisions or determinations approved by the Joint Development Committee
and a list of any issues to be resolved by the Executive Officers.  The
chairperson or the secretary of Kissei shall then have 10 days after receiving
such draft minutes to collect Kissei members= comments thereon and provide them
to the chairperson or the secretary of Inspire.  Upon the expiration of such
second 10-day period, the chairperson and the secretary of the Joint Development
Committee shall have an additional 10 days to discuss each other's comments and
finalize the minutes.  The secretary and chairperson shall each sign and date
the final minutes.  The signature of the chairperson and the secretary upon the
final minutes shall indicate each Party=s assent to the minutes.  With the sole
exception of specific items of the meeting minutes to which the chairperson and
the secretary cannot agree and which are escalated as provided below, definitive
minutes of all Joint Development Committee meetings shall be finalized no later
than 30 days after the meeting to which the minutes pertain.  If at any time
during the preparation and finalization of Joint Development Committee meeting
minutes the secretary and the chairperson do not agree on any issue with respect
to the minutes, such issue shall be resolved by the escalation process provided
in Section 3.4(b).  The decision resulting from the escalation process shall be
recorded by the chairperson or the secretary

                                      -10-
<PAGE>

of Inspire in amended finalized minutes for said meeting.  All other issues in
the minutes which are not subject to such escalation shall be finalized within
the above-mentioned 30-day period.

     3.6  Term.    The Joint Development Committee shall exist until the
termination or expiration of the Joint Development Program and for such longer
period as necessary to perform the responsibilities assigned to it under this
Agreement.

     3.7  Expenses.    Each Party shall be responsible for all travel and
related costs and expenses for its members and approved invitees to attend
meetings of, and otherwise participate on, the Joint Development Committee.

4.   JOINT DEVELOPMENT PROGRAM.

     4.1  Scope of Joint Development Program.

          (a) The Joint Development Committee, acting in accordance with
Sections 3.2(b) and (c), shall prepare and provide to each Party, in form and
substance mutually acceptable to each Party, a detailed description of the
specific actions to be taken under the Joint Development Program during the
upcoming year, which shall include a reasonably detailed description of the
goals and scope of such research, the allocation of responsibilities to the
respective Parties and a research plan (each, an "Annual Development Plan").

          (b) If the Joint Development Committee fails to agree on an Annual
Development Plan: (i) the Parties nevertheless shall continue to fund the Joint
Development Program in accordance with Section 4.6; (ii) each Party nevertheless
shall continue to conduct the Joint Development Program in accordance with the
goals and scope of such research as reasonably determined by such Party, within
the scope of the Joint Development Program conducted to date (or, with respect
to the first year of the Joint Development Program, within the scope of this
Agreement); and (iii) Inspire nevertheless shall continue to supply Compound,
Finished Product and Delivery Systems necessary for the conduct of the Joint
Development Program in accordance with this Section 4.

     4.2  Specific Kissei Responsibilities.    As part of the Joint Development
Program, and pursuant to the Annual Development Plans, Kissei shall:

          (a)  Conduct, or cause to be conducted, manage and oversee any pre-
clinical studies, or additional pre-clinical studies, required by the Regulatory
Authorities in order to file an NDA for the Product in the Territory; (b)
Conduct, or cause to be conducted, manage and oversee all clinical studies
required by the Regulatory Authorities in order to obtain NDA Approvals for the
Product in the Territory;

                                      -11-
<PAGE>

          (c) Make all regulatory filings, based on the information and
documentation provided by Inspire, and conduct all analysis and other support
necessary with respect to the manufacture of the Finished Product, Delivery
Systems or Product in the Territory; and

          (d) Perform such other obligations with respect to the Joint
Development Program as the Joint Development Committee may assign to it from
time to time.

     4.3  Specific Inspire Responsibilities.    As part of the Joint Development
Program and pursuant to the Annual Development Plans, Inspire shall:

          (a) Immediately after the Effective Date, provide to Kissei copies of
all pre-clinical and clinical data, studies and materials in Inspire's
possession and control that relate to the development and commercialization of
the Product;

          (b) Thereafter provide to Kissei copies of all data, studies and
material that come into Inspire's possession and control during the term of this
Agreement that relate to the development and commercialization of the Product
(including, without limitation, such data, studies and materials of Strategic
Partners, to the extent Inspire has the right to provide same to Kissei);

          (c) In consultation with Kissei, finalize the design of and the
manufacturing process for the Delivery System and the Finished Product, subject
to review and approval of the Joint Development Committee;

          (d) In consultation with Kissei, make all necessary changes to: (i)
the formulation, chemistry,  manufacturing process and manufacturing controls
for the Compound, Formulated Material and Finished Product; and (ii) the design
and manufacturing method for the Delivery System and the Finished Product,
subject in each case to review and approval of the Joint Development Committee;

          (e)  Supply Kissei or its designee(s) with sufficient quantities of
the Compound and/or the Formulated Material to complete all pre-clinical studies
of the Product in which Kissei is required to engage by the applicable
Regulatory Authorities until the filing of, or the affirmative decision of the
Joint Development Committee not to pursue, an IND with respect to the Product in
the Territory.  Such Compound and/or Formulated Material shall be supplied in
accordance with quarterly forecasts therefor provided by Kissei at least 180
days prior to the anticipated delivery date for each shipment thereof, provided,
however, in the event that Kissei requires Compound and/or Formulated Material
in fewer than 180 days, Kissei shall notify Inspire of such need and Inspire
will use all reasonable efforts to meet Kissei's delivery request;

                                      -12-
<PAGE>

          (f) Supply Kissei or its designee(s) with sufficient quantities of
Finished Product and Delivery Systems to complete all clinical studies and all
development, analysis, regulatory support, cGMP and all other NDA Approval-
related activities with respect to the Product in which Kissei is required to
engage by applicable law or regulation until the commercial launch, or the
affirmative decision of the Joint Development Committee not to pursue the
commercial launch, of the Product in the Territory. Such Finished Product and
Delivery Systems shall be supplied in accordance with quarterly forecasts
therefor provided by Kissei at least 180 days prior to the anticipated delivery
date for each shipment of Finished Product or Delivery Systems, provided,
however, in the event that Kissei requires Finished Product and/or Delivery
Systems in fewer than 180 days, Kissei shall notify Inspire of such need and
Inspire will use all reasonable efforts to meet Kissei's delivery request;

          (g) As Inspire and its Third Party Manufacturers gain knowledge and
experience in producing the pre-clinical and clinical supplies required pursuant
to Sections 4.3(e) and (f), use reasonable efforts to reduce the lead time
needed to manufacture Compound, Formulated Material, Finished Product and/or
Delivery Systems such that Inspire could be in a position to meet Kissei's
delivery requirements on fewer than 180 days prior notice;

          (h) Designate and maintain coordinator/liaisons in accordance with
Section 4.4;

          (i) Negotiate in good faith with all relevant Strategic Partners to
obtain the right to: (i) disclose to Kissei all Third Party data or information
owned by such Strategic Partners that this Agreement contemplates will be shared
with Kissei to the extent that Inspire has the right to do so, and (ii) grant
Kissei the right to cross-reference regulatory filings owned by such Strategic
Partners that this Agreement contemplates will be granted to Kissei to the
extent that Inspire has the right to do so; and

          (j) Perform such other obligations with respect to the Joint
Development Program as the Joint Development Committee may assign to it from
time to time.

     4.4  Coordinator/Liaison Functions.    Within 90 days after the Effective
Date, Inspire shall designate two FTEs, to be funded by Kissei pursuant to
Section 6.2, who shall perform the following functions:

          (a)  One FTE shall serve as a project manager (the "Development
Coordinator/Liaison") who shall be responsible for coordinating, and
facilitating communication regarding, the worldwide development of the Product
among Inspire, Kissei and Inspire's other strategic partners and/or licensees
(collectively, "Strategic Partners").  Inspire shall continue to provide a
Development Coordinator/Liaison until NDA Approval for the Product is received,
or definitively abandoned, in the Territory, whichever occurs first; and

                                      -13-
<PAGE>

     (b) The second FTE shall serve as a project manager (the "Manufacturing
Coordinator/Liaison") who shall be responsible for coordinating, and
facilitating communication regarding, the design and development of the Delivery
System and the Finished Product, the manufacture of the Compound, the
formulation of the Formulated Material and the manufacture of the Product among
Inspire, Kissei and Inspire's Strategic Partners. Inspire shall continue to
provide a Manufacturing Coordinator/Liaison until Kissei files the NDA for the
Product with the Regulatory Authority in the Territory , or until definitely
abandoned, whichever occurs first. Thereafter Inspire shall continue to provide
a Manufacturing Coordinator/Liaison as and when determined by the Joint
Development Committee.

Each such coordinator/liaison shall maintain regular communication with Kissei
and each of Inspire's Strategic Partners with respect to the matters for which
such coordinator/liaison is responsible.  Such communication may include
attendance of meetings and telephone conferences to be held from time to time,
at the request and convenience of the Parties and any Third Parties involved.

     4.5  Regulatory Matters.

          (a) Kissei shall be responsible for preparing and filing INDs, NDAs
and other regulatory filings for the Product in the Territory up to and
including NDA Approval, and thereafter shall be responsible for maintaining such
NDA Approvals.  All such filings shall be in Kissei's name.

          (b) Kissei shall own all INDs, NDAs, NDA Approvals and other
regulatory filings for the Product in the Territory.

          (c) In order to assist Kissei in the performance of its obligations
under this Section 4.5, Inspire, to the extent it has the right to do so, shall
provide Kissei or its designee(s) with complete copies (or copies of relevant
portions) of, and shall grant Kissei or its designee(s), free of charge, the
right to cross-reference, any INDs, NDAs, NDA Approvals or other regulatory
filings made or held in any country in North America and Europe for the Product.
Inspire shall execute, acknowledge and deliver such further instruments, and
shall do all such other acts, all as promptly as possible after Kissei's request
therefor, that may be necessary or appropriate to effectuate such right in each
such country.  Inspire shall not guarantee or warrant that the information and
documents provided to Kissei under this Section shall be useful or effective or
free from any defect.

          (d) Kissei shall provide Inspire with complete copies (or copies of
relevant portions) of, and shall grant Inspire free of charge the right to
cross-reference any INDs, NDAs, NDA Approvals or other regulatory filings made
or held in the Territory in the name of Kissei (or that of its Affiliates or
Sublicensees) reasonably necessary or useful to enable Inspire to market
products either within the Territory and outside the Field, or outside the
Territory.  Kissei shall execute, acknowledge and deliver such further
instruments, and shall do all such other acts, all as promptly as possible after
Inspire's request therefor, that may be necessary or appropriate to effectuate
such right in the Territory.  Kissei also shall provide such copies and such
right to cross-

                                      -14-
<PAGE>

reference, free of charge, to any Strategic Partner that grants Kissei or its
designee(s) the right to cross-reference such Strategic Partner's INDs, NDAs,
NDA Approvals or other regulatory filings made or held in any countries in North
America and/or Europe to enable such Strategic Partner to market products
outside the Territory in North America and Europe, and any other countries in
which such Strategic Partners hold such rights.  Moreover, Kissei shall provide
such copies and such right to cross-reference, with a reasonable charge, to any
Strategic Partner that does not have rights in any countries in North America
and/or Europe to enable such Strategic Partner to market products outside the
Territory in such countries.  Kissei shall not guarantee or warrant that the
information and documents provided to Inspire under this Section shall be useful
or effective or free from any defect.

          (e) Kissei shall keep Inspire informed as to the status of all
regulatory filings made pursuant to this Section 4.5, permit Inspire to review
any revisions to any filings or communications with Regulatory Authorities
during their preparation and shall confer with Inspire regarding the preparation
of such filings, communications with Regulatory Authorities and other matters
pertaining to or affecting the registration process.

          (f) In connection with any IND or NDA filed by Kissei pursuant to this
Section 4.5, Kissei shall notify Inspire as soon as reasonably possible of any
meeting with the Regulatory Authority in the Territory scheduled by Kissei
(which notification shall describe the subject matter of any such meeting),
shall permit Inspire to assist Kissei in the preparation for any such meeting
and shall promptly advise Inspire in writing of the outcome of any such meeting.

     4.6  Funding of Joint Development Program.

          (a) Except as otherwise expressly provided in this Agreement, each
Party shall bear the entire cost and expense it incurs in connection with
fulfillment of its obligations under the Joint Development Program.

          (b) Kissei shall pay [CONFIDENTIAL TREATMENT REQUESTED], as the case
may be, in connection with the manufacture and supply of Compound, Formulated
Material, Finished Product and Delivery Systems pursuant to Sections 4.3(e) and
(f).  Inspire shall be entitled to invoice Kissei therefor following shipment of
such Compound, Formulated Material, Finished Product and Delivery Systems from
time to time.  Payment shall be made by Kissei in U.S. Dollars within 30 days
after Kissei's receipt of each invoice therefor, by telegraphic transfer
remittance.

     4.7  Conduct of Joint Development Program.    The Parties, acting in
accordance with this Section 4 and relevant Annual Development Plans, shall use
all commercially reasonable efforts to develop the Product in the Territory.
Kissei, acting in accordance with this Section 4 and relevant Annual Development
Plans, shall use all commercially reasonable efforts to obtain NDA Approvals

                                      -15-
<PAGE>

necessary to market and sell the Product in the Territory.  Without limiting the
generality of the foregoing, during the term of the Joint Development Program,
each Party shall:

          (a) undertake an interactive, cooperative Joint Development Program
with the other Party as set forth in the applicable Annual Development Plan, and
such other activities that, from time to time, the Joint Development Committee
decides are necessary for the commercial success of the Joint Development
Program;

          (b) use all reasonable efforts and proceed diligently to perform the
work set out for such Party to perform in the Annual Development Plan,
including, without limitation, by using personnel with sufficient skills and
experience, together with sufficient equipment and facilities (it being
acknowledged that neither Party shall have an obligation to acquire additional
equipment or to expand its facilities in order to perform its obligations under
the Joint Development Program);

          (c) conduct the Joint Development Program in good scientific manner,
and in compliance in all material respects with all requirements of applicable
laws, rules and regulations, and all other requirements of any applicable
current good clinical practice, good laboratory practice and current good
manufacturing practice to attempt to achieve the objectives of the Joint
Development Program efficiently and expeditiously;

          (d) within 30 days after the end of each six-month period during the
term of the Joint Development Program and within 30 days following the
expiration or termination of the Joint Development Program, furnish the Joint
Development Committee with reasonably detailed, written reports on all
activities conducted by such Party under the Joint Development Program during
such six-month period or the term of the Joint Development Program, as the case
may be;

          (e) maintain records, in sufficient detail and in good scientific
manner, which shall be complete and accurate and shall fully and properly
reflect all work done and results achieved in connection with the Joint
Development Program in the form required under all applicable laws and
regulations.  Each Party shall have the right, during normal business hours and
upon reasonable notice, to inspect and copy all such records.  Each Party shall
maintain such records and information contained therein in confidence in
accordance with Section 10 and shall not use such records or information except
to the extent otherwise permitted by this Agreement; and

          (f) allow representatives of the other Party, upon reasonable notice
and during normal business hours, to visit such Party's facilities where the
Joint Development Program is being conducted, and consult, during such visits
and by telephone, with such Party's personnel performing work on the Joint
Development Program.

     4.8  Liability.    Each Party shall be responsible for, and hereby assumes,
any and all risks of personal injury or property damage attributable to the
negligent or willful acts or omissions,

                                      -16-
<PAGE>

during the term of the Joint Development Program, of such Party or its
Affiliates, and their respective directors, officers, employees and agents.

5.   GRANT OF RIGHTS; COMMERCIALIZATION; MARKETING.

     5.1  Development Licenses.

          (a) Inspire hereby grants to Kissei, during the term of the Joint
Development Program, the exclusive (except as to Inspire), paid-up license, with
the right to grant sublicenses solely to the extent provided in Section 5.3(a),
under the Licensed Technology, to conduct the Joint Development Program.

          (b) Kissei hereby grants to Inspire, during the term of the Joint
Development Program, the exclusive (except as to Kissei), paid-up license, with
no right to grant sublicenses (except to the extent necessary to conduct the
Joint Development Program), under Kissei's interest in any Inventions, to
conduct the Joint Development Program.

     5.2  Commercialization License.    Inspire hereby grants to Kissei an
exclusive (even as to Inspire) license throughout the Territory, with the right
to grant sublicenses in accordance with the terms of this Agreement, under the
Licensed Technology, to develop, use, market and sell Products in the Field.
With respect to any such Patents that may issue in Japan during the term of this
Agreement, a  statement referencing the exclusive license granted to Kissei
pursuant to this Section 5.2 shall be registered with the Japanese Patent Office
at Kissei=s cost, as soon as is practically possible after the issuance of the
respective Patents.  Inspire hereby agrees that it will execute such documents
and instruments as may be required to effect the registration of such statement
and otherwise cooperate with Kissei in connection with the registration of such
statement with the Japanese Patent Office.

     5.3  Sublicensing.

          (a) Solely in connection with the grant of a sublicense of the
licenses granted to Kissei under Section 5.2, Kissei shall have the right to
grant a sublicense of the licenses granted to Kissei under Section 5.1(a) for
purposes of such Affiliates' or Sublicensees' performance of Kissei's
obligations under Section 4, provided that, in addition to the requirements set
forth in Section 5.3(b), each Affiliate or Sublicensee agrees in writing to
maintain scientific records and permit Inspire to inspect and copy such records
and visit such facilities pursuant to the relevant provisions of Section 4.7,
and to observe all other applicable terms, of this Agreement.

          (b) Kissei shall have the right to grant sublicenses to any of its
Affiliates or Sublicensees of the licenses granted to Kissei under Section 5.2
for purposes of such Affiliates' or Sublicensees' performance of Kissei's
obligations under Section 5.5, provided that: (i) Kissei shall

                                      -17-
<PAGE>

submit all proposed sublicenses to Inspire for approval, which approval shall
not be unreasonably withheld; (ii) Kissei shall guarantee and be responsible for
the making of all payments due, and the making of any reports under this
Agreement, with respect to sales of Product by its Affiliates or Sublicensees
and their compliance with all applicable terms of this Agreement; and (iii) each
Affiliate or Sublicensee agrees in writing to maintain books and records and
permit Inspire to review such books and records pursuant to the relevant
provisions, and to observe all other applicable terms, of this Agreement.
Kissei shall promptly provide Inspire with notice of any sublicense granted
pursuant to this Section 5.3, and provide a copy of the sublicense to Inspire
upon its request.

          (c) Kissei hereby unconditionally guarantees the performance of any of
its  Affiliates and Sublicensees hereunder.  In the event of a breach by such an
Affiliate or Sublicensee in the observance of applicable terms of this
Agreement, Inspire shall be entitled to proceed against either such Affiliate or
Sublicensee or directly against Kissei, as Inspire may determine in its sole
discretion, to enforce this Agreement.

     5.4  Grantback Rights.    Subject to the terms and conditions of this
Agreement, Kissei hereby grants to Inspire:

          (a) With respect to any unpatented know-how that embodies or relates
to Inventions and that are owned or controlled by Kissei or its Affiliates, an
exclusive (except as to Kissei), paid-up, perpetual license thereunder: (i) to
develop, make, have made, use, offer to sell, sell and have sold products with
applications outside the Field for all purposes worldwide (including, without
limitation, within the Territory), and  (ii) to develop, make, have made, use,
offer to sell, sell and have sold Products with applications within the Field
for all purposes outside the Territory.  The foregoing licenses shall include
the right to grant sublicenses.

          (b) With respect to any patents or patent applications that embody or
relate to Inventions and that are owned or controlled by Kissei or its
Affiliates, an exclusive (except as to Kissei), paid-up, perpetual license
thereunder, to develop, make, have made, use, offer to sell, sell and have sold
Products with applications within the Field for all purposes outside the
Territory.  The foregoing licenses shall include the right to grant sublicenses.

          (c) With respect to any patents or patent applications that embody or
relate to Inventions and that are owned or controlled by Kissei or its
Affiliates, an exclusive (except as to Kissei)  license, with fees and royalties
as consideration to Kissei, to develop, make, have made, use, offer to sell,
sell and have sold products with applications outside the Field for all purposes
worldwide (including, without limitation, within the Territory); provided that
Inspire shall grant Kissei a right of first offer with respect to co-development
and co-marketing of products covered by such Inventions.  The foregoing licenses
shall include the right to grant sublicenses.  The Parties shall negotiate the
license fees and royalty rates for the license to such Inventions in good faith
and consistent with customary business practices therefor and the other terms
and conditions set forth in this Agreement.

                                      -18-
<PAGE>

     5.5  Commercialization Obligations, Rights.    Kissei shall use all
commercially reasonable efforts to develop and commercialize the Product in the
Territory.  In connection therewith, Kissei shall dedicate resources to the
development and commercialization of the Product consistent with the resources
that Kissei, at all relevant times, would dedicate to products containing
compounds that were generated from Kissei's own research efforts which Kissei
decided to develop commercially and market and that have pricing, volume and
marketing potentials similar to those of the Product.  Kissei, either itself
and/or by and through its Affiliates and Sublicensees, shall be responsible for,
and shall have the exclusive right to engage in, all marketing, advertising,
promotional,  launch and sales activities in connection with such efforts.

     5.6  Right of First Refusal.    [CONFIDENTIAL TREATMENT REQUESTED]

     5.7  Adverse Reaction Reporting.

          (a) Each Party shall record, evaluate, summarize and review all
adverse drug experiences associated with the Compound and the Product.  In order
that each Party may be fully informed of the adverse drug experiences associated
therewith that are known to the other Party, each Party shall report:

                                      -19-
<PAGE>

               (i)  In the case of Inspire, to:

                    Inspire Pharmaceuticals, Inc.
                    4222 Emperor Boulevard, Suite 470
                    Durham, North Carolina  27703
                    USA
                    Attention:  Patricia Edgar, Ph.D., Director, Regulatory
                                Affairs
                    Facsimile No.: (919) 941-9797
                    Telephone No.: (919) 941-9777 ext. 277

               (ii)  In the case of Kissei, to:

                    Kissei Pharmaceutical Co., Ltd.
                    1-3, Koishikawa
                    3-Chome, Bunkyo-Ku, Tokyo
                    112-0002
                    JAPAN
                    Attention:  Haruo Suzawa, Ph.D., Director, Member of the
                                Board, Clinical Development, R & D
                    Facsimile No.: (03)5804-8560
                    Telephone No.: (03)5684-3539

all "adverse events," as defined by the then current ICH guidelines, involving
the Compound and/or the Product (all such reports, "AE Reports").  "Serious"
adverse events shall be reported to the other Party within three working days
after a Party's (a "reporting Party") becoming aware of such an event and shall
either be reported by facsimile or telephone.  The reporting Party shall report
on a quarterly basis all other adverse events that are known to the reporting
Party through either the receipt of clinical study documentation or post-market
surveillance.  In addition, the reporting Party shall report all known instances
of use of the Product during pregnancy.  In any event, each Party shall promptly
notify the other of any complaint received by such Party in sufficient detail
and in sufficient time to allow the responsible Party to comply with any and all
regulatory requirements imposed upon it in the Territory.  Each Party shall also
advise the other of any regulatory developments (e.g., proposed recalls,
labeling and other registrational dossier changes, etc.) affecting the Compound
or the Product in the Territory.

          (b) According to current ICH guidelines, an "adverse event" is any
untoward medical occurrence in a patient or clinical investigation subject
administered a pharmaceutical product, which occurrence does not necessarily
have to have a causal relationship with the treatment.

          (c) According to current ICH guidelines, a "serious" adverse event is
any untoward medical occurrence that, at any dose, results in death, is life-
threatening (at the time of the

                                      -20-
<PAGE>

event), requires inpatient hospitalization or prolongation of existing
hospitalization, results in persistent or significant disability or incapacity,
or is a congenital anomaly or birth defect.

          (d) The details of adverse reaction reporting during development stage
and thereafter shall be stipulated in separate agreements to be entered into by
the Parties in due course.

6.   FEES, MILESTONES AND ROYALTIES.

     6.1  Up-front Payment.

          (a) As partial consideration to Inspire for the license and other
rights granted to Kissei under this Agreement, upon the execution of this
Agreement by both Parties, Kissei shall pay to Inspire the sum of [CONFIDENTIAL
TREATMENT REQUESTED] in connection with the license and other rights in the
Territory.  Such sum shall be non-refundable.

          (b) As further consideration to Inspire for the license and other
rights granted to Kissei under this Agreement, pursuant to the Stock Purchase
Agreement and simultaneously with the execution of this Agreement, Kissei is
purchasing 375,000 shares of Inspire's Series C Preferred Stock for an aggregate
purchase price of US$900,000.

     6.2  Coordinator/Liaison Fees.    As consideration to Inspire for
designating and maintaining the Development Coordinator/Liaison and the
Manufacturing Coordinator/Liaison:

          (a) For every calendar year during which Inspire maintains a
Development Coordinator/Liaison, Kissei shall pay Inspire the sum of
[CONFIDENTIAL TREATMENT REQUESTED], which shall be payable, in advance, on the
first day of each calendar quarter, in equal installments, until NDA Approval
for the Product is received, or definitively abandoned, in the Territory,
whichever occurs first; and

          (b) For every calendar year during which Inspire maintains a
Manufacturing Coordinator/Liaison, Kissei shall pay Inspire the sum of
[CONFIDENTIAL TREATMENT REQUESTED], which shall be payable, in advance, on the
first day of each calendar quarter, in equal installments until Kissei files the
NDA for the Product with the Regulatory Authority in the Territory , or until
definitely abandoned, whichever occurs first.  Thereafter Kissei shall continue
to make such payments for the Manufacturing Coordinator/Liaison as and when
determined by the Joint Development Committee.  In addition, during any period
when Kissei is paying such amount for the Manufacturing Coordinator/Liaison,
Kissei shall also reimburse Inspire for all reasonable travel, lodging, meals
and other necessary out-of-pocket expenses incurred by Inspire in connection
with the Manufacturing Coordinator/Liaison's performance of his or her
obligations under this Agreement.In addition, on the Effective Date, Kissei
shall pay Inspire a quarterly installment of each of the Development
Coordinator/Liaison fee and the Manufacturing Coordinator/Liaison fee, pro rated
for

                                      -21-
<PAGE>

the number of days remaining after the Effective Date in the calendar quarter in
which the Effective Date falls.  Similarly, Inspire shall refund to Kissei such
portion of quarterly installment of each of the Development Coordinator/Liaison
fee and the Manufacturing Coordinator/Liaison fee as prorated for the number of
days remaining after the termination of each of their services in the calendar
quarter in which the termination occurs.

     6.3  Milestone Payments.    As further consideration to Inspire for the
license and other rights granted to Kissei under this Agreement, Kissei shall
pay to Inspire the following milestone payments upon the first occurrence of
each event set forth below with respect to each Product:

[CONFIDENTIAL TREATMENT REQUESTED]

          Each of the payments required pursuant to this Section 6.3 shall be
paid within 30 days after such milestone has been achieved.

     6.4  Transfer Price.

          (a) The transfer price to Kissei for the Supplied Goods shall be an
amount equal to [CONFIDENTIAL TREATMENT REQUESTED] (the "Transfer Price").

          (b) Notwithstanding Section 6.4(a), in the event and to the extent
that Kissei provides Delivery Systems to health care providers and/or patients
at a nominal charge or no charge,

                                      -22-
<PAGE>

          Inspire and Kissei will negotiation in good faith for [CONFIDENTIAL
TREATMENT REQUESTED].

(c)  [CONFIDENTIAL TREATMENT REQUESTED]

     6.5  Royalty Payments.    As further consideration to Inspire for the
license and other rights granted to Kissei under this Agreement, during the term
of this Agreement, Kissei shall pay to Inspire a royalty on Net Sales of the
Product commencing on the First Commercial Sale of the Product by Kissei, its
Affiliates or its Sublicensees, on a Product-by-Product basis, in an amount
equal to [CONFIDENTIAL TREATMENT REQUESTED] of the aggregate Net Sales of the
Product by Kissei, its Affiliates and its Sublicensees throughout the Territory.
Notwithstanding the foregoing, the royalty rate shall be reduced to
[CONFIDENTIAL TREATMENT REQUESTED] with respect to a Product when such Product
ceases to be covered by any Licensed Claims in the Territory or when one or more
Third Parties markets a generic product.  For purposes of this provision,
"generic product" means a Third Party product: (i) having as a pharmaceutically
active ingredient the same Compound or its salt as such Product, AND (ii) where
the manufacture, use or sale of such Third Party product is not covered by a
Licensed Claim.  Such reduced royalty rate shall be effective for the first full
calendar quarter commencing after the date of any such event.

     6.6  Obligation to Pay Royalties.   The obligation to pay royalties to
Inspire under this Section 6 is imposed only once with respect to the same unit
of Product regardless of the number of Patents or quantity of Know-how
pertaining thereto.  There shall be no obligation to pay royalties to Inspire
under this Section 6 on sales of Product between Kissei and its Affiliates and
Sublicensees, but in such instances the obligation to pay royalties shall arise
upon the sale by Kissei or its Affiliates or Sublicensees to unrelated Third
Parties.  Payments due under this Section 6 shall be deemed to accrue when
Product is billed.

                                      -23-
<PAGE>

7.   PAYMENTS AND REPORTS.

     7.1  Payments.

          (a) Inspire shall submit invoices to Kissei for the Transfer Price of
Supplied Goods promptly after each shipment thereof.  Each such invoice shall
include any previously uninvoiced adjustments to the Cost of Delivery Systems
pursuant to Section 6.4(b).  Payments shall be made by Kissei within 30 days
after Kissei's receipt of each invoice therefor, by telegraphic transfer
remittance.

          (b) Beginning with the calendar quarter in which the First Commercial
Sale of Products is made in the Territory and for each calendar quarter
thereafter, Kissei shall submit a statement, Product-by-Product, of the amount
of Net Sales during such quarter and the amount of royalties due on such Net
Sales.  Each such statement shall also include information on the number of
Delivery Systems delivered by Kissei during such calendar quarter and the price
Kissei charged therefor.  Each such statement shall be accompanied by payment of
the royalties due.  The statement, together with the accompanying payment, shall
be submitted quarterly within 30 days after the end of each calendar quarter.

     7.2  Mode of Payment.    All invoices submitted by Inspire shall be stated
in U.S. Dollars. Kissei shall make all payments required under this Agreement as
directed by Inspire from time to time, net of any out-of-pocket transfer costs
or fees, in U.S. Dollars.  All payments due shall be translated at the
Telegraphic Transfer Selling rate (TTS) quoted by Tokyo Mitsubishi Bank, Japan
on the day and time of remittance.

     7.3  Records Retention.    Kissei and its Affiliates and Sublicensees shall
keep complete and accurate records pertaining to the sale of Products, and
Inspire shall keep complete and accurate records pertaining to Inspire's Cost of
Compound, Formulated Material, Cost of Finished Product and Cost of Delivery
Systems, for a period of three calendar years after the year in which such sales
or costs occurred, and in sufficient detail to permit the other Party to confirm
the accuracy of the aggregate royalty and/or Transfer Price calculations
hereunder.

     7.4  Audit Request.

          (a) At the request and expense of Inspire, Kissei and its Affiliates
and Sublicensees shall permit an independent, certified public accountant
appointed by Inspire and reasonably acceptable to Kissei, at reasonable times
and upon reasonable notice, to examine such records as may be necessary to: (i)
determine the correctness of any report or payment made under this Agreement; or
(ii) obtain information as to the aggregate Transfer Price and/or royalties
payable for any calendar quarter in the case of Kissei's failure to report or
pay pursuant to this Agreement.  Said accountant shall not disclose to Inspire
any information other than information relating to said

                                      -24-
<PAGE>

reports, royalties, and payments. Results of any such examination shall be made
available to both Parties.

          (b) At the request and expense of Kissei, Inspire shall permit an
independent, certified public accountant appointed by Kissei and reasonably
acceptable to Inspire, at reasonable times and upon reasonable notice, to
examine those records as may be necessary to verify the aggregate Cost of
Compound, Cost of Formulated Material, Cost of Finished Product and/or Cost of
Delivery Systems incurred for any period.  Said accountant shall not disclose to
Kissei any information other than information relating to said Cost of Compound,
Cost of Formulated Material, Cost of Products and/or Cost of Delivery Systems.
Results of any such examination shall be made available to both Parties.

     7.5  Cost of Audit.

          (a) Inspire shall bear the full cost of the performance of any audit
requested by Inspire except as hereinafter set forth.  If, as a result of any
inspection of the books and records of Kissei, its Affiliates or its
Sublicensees, it is shown that Kissei's payments under this Agreement were less
than the amount which should have been paid, then Kissei shall make all payments
required to be made to eliminate any discrepancy revealed by said inspection
within 30 days after Inspire's demand therefor.  Furthermore, if the payments
made were less than 95% of the amount that should have been paid during the
period in question, Kissei shall also reimburse Inspire for the reasonable costs
of such audit and shall make such payment required to be made to eliminate such
discrepancy.

          (b) Kissei shall bear the full cost of the performance of any audit
requested by Kissei except as hereinafter set forth.  If, as a result of any
inspection of the books and records of Inspire, it is shown that Inspire
overstated its Cost of Compound, Cost of Formulated Material, Cost of Finished
Product and/or Cost of Delivery Systems under this Agreement for any period,
then Kissei shall be entitled to a credit in the amount necessary to eliminate
any discrepancy revealed by said inspection.  Such credit may be applied against
any amounts due and owing to Inspire pursuant to this Agreement (e.g.,
milestones, royalties, Transfer Price).  Furthermore, if the amounts for any
period were overstated by more than five percent, Inspire shall also reimburse
Kissei for the reasonable costs of such audit and shall make such payment
required to be made to eliminate such discrepancy.

     7.6  No Non-Monetary Consideration for Sales.    Without the prior written
consent of Inspire, Kissei and its Affiliates and Sublicensees shall not accept
or solicit any non-monetary consideration of the sale of the Product other than
as would be reflected in Net Sales.  The use by Kissei and its Affiliates and
Sublicensees of a commercially reasonable amount of Product for promotional
sampling shall not violate this Section 7.6.

                                      -25-
<PAGE>

     7.7  Taxes.

          (a) In the event that Kissei is required to withhold any tax to the
tax or revenue authorities in the Territory regarding any payment to Inspire due
to the laws of such country, such amount shall be deducted from the payment to
be made by Kissei, and Kissei shall notify Inspire and promptly furnish Inspire
with copies of any tax certificate or other documentation evidencing such
withholding.  Each Party agrees to cooperate with the other party in claiming
exemptions from such deductions or withholdings under any agreement or treaty
from time to time in effect.

          (b) If  Inspire has the legal obligation to collect and/or pay any
sales, use, excise or value added taxes, the appropriate amount shall be added
to Kissei's invoice and paid by Kissei, unless Kissei provides Inspire with a
valid tax exemption certificate authorized by the appropriate taxing authority.

8.   MANUFACTURE AND SUPPLY.

     8.1  Commercial Supply Agreement.    Both Parties recognize the importance
of Inspire  establishing and maintaining a reliable and steady source of supply
of Finished Product and Delivery Systems (collectively, "Supplied Goods") for
commercial marketing in the Territory by Kissei so that supply shortages do not
occur.  Commencing on the Effective Date, Inspire intends to work toward that
goal with its Third Party Manufacturers, and will keep Kissei informed, through
the Joint Development Committe, of the actions being undertaken by Inspire to do
so.  Inspire shall also give Kissei, through the Joint Development Committee or
otherwise, as Kissei may desire, an opportunity to review Inspire's actions and
provide input into other actions deemed appropriate.  At such time as the Joint
Development Committee determines is appropriate, the Parties shall negotiate in
good faith the terms of a commerical supply agreement to be entered into by the
Parties (the "Supply Agreement") pursuant to which Inspire shall provide Kissei
with its commercial supply requirements of Supplied Goods.  The Supply Agreement
shall contain mutually acceptable terms and conditions, substantially consistent
with the terms and conditions set forth on Exhibit D.

9.   OWNERSHIP; PATENTS.

     9.1  Ownership.

          (a) Except as otherwise provided in Section 9.1(b) or (c), Inspire
shall retain all right, title and interest in and to the Patents and Know-how,
regardless of which Party prepares and prosecutes the applications associated
therewith, or maintains the patents, copyrights or other intellectual property
rights related thereto, subject to the license granted to Kissei pursuant to
Section 5.2.  Rights to Inventions made solely by employees of Inspire shall
belong to Inspire.

                                      -26-
<PAGE>

Notwithstanding any other provision of this Agreement, Kissei shall not own any
right, title or interest in and to any Inventions relating to the Cassette or
Delivery System.

          (b) Rights to Inventions made solely by employees of Kissei shall
belong to Kissei.

          (c) Rights to Inventions which were made jointly by employees of
Inspire and by employees of Kissei shall belong jointly to Inspire and to
Kissei.  Such joint Inventions shall be subject to the terms and conditions of
this Agreement.

          (d) Inspire shall not own any right, title or interest in any
trademark or  trade name selected by Kissei or the Joint Development Committee
to appear on any Product label or to be inscribed on any Product or component
part thereof.

     9.2  Patent Maintenance.

          (a) Inspire shall have full responsibility for, and shall control the
preparation and prosecution of, all patent applications and the maintenance of
all patents relating to the Licensed Technology (including the Patents)
throughout the Territory.  Inspire shall pay all costs  and expenses of filing,
prosecuting and maintaining the Patents and the patents covering Inventions
owned by Inspire in the Territory.

          (b) Inspire shall select qualified independent patent counsel to file
and prosecute all patent applications pursuant to Section 9.2(a).  Inspire shall
provide copies to Kissei of any filings made to, and written communications
received from, any patent office relating, in whole or in part, to the Licensed
Claims.

          (c) Each Party agrees promptly to provide to the other Party a
complete written disclosure of any Invention made by such Party.  Inspire shall
determine whether any Invention owned solely by Inspire or jointly by Inspire
and Kissei is patentable, and if so, shall proceed with the preparation and
prosecution of a patent application covering any such Invention. Kissei shall
determine whether any Invention owned solely by Kissei is patentable, and if so,
shall proceed with the preparation and prosecution of a patent application
covering any such Invention.

          (d) Inspire and Kissei shall share all costs and expenses of filing,
prosecuting and maintaining the Patents and the patents covering Inventions
owned jointly by Kissei and Inspire in the Territory.  If either Party elects
not to pay for: (i) the filing of a patent application in the Territory on any
such Patent or Invention which the other Party reasonably believes is
patentable, or (ii) the further prosecution or maintenance of any such Patent or
Invention in the Territory, or (iii) the filing of any divisional or continuing
patent application based on any Patent or Invention in the Territory, such Party
shall notify the other Party in a timely manner and the other Party may do so at
its own expense.  In such event, such patent or application in the Territory
shall be assigned by such Party

                                      -27-
<PAGE>

to the other Party, all of such assigning Party's rights in such patent or
application in the Territory shall cease, and, in the case where Kissei is the
assigning Party, the license granted to Kissei under Section 5.2 with respect
thereto shall terminate.

          (e) Each Party agrees to cooperate with the other Party to execute all
lawful papers and instruments, to make all rightful oaths and declarations and
to provide consultation and assistance as may be necessary in the preparation,
prosecution, maintenance, and enforcement of all such patents.

     9.3  Patent Enforcement.

          (a) If either Party learns of an infringement, unauthorized use,
misappropriation  or ownership claim or threatened infringement or other such
claim (an "infringement") by a Third Party with respect to any Licensed
Technology within the Territory, such Party shall promptly notify the other
Party and shall provide such other Party with available evidence of such
infringement.  In addition, Inspire shall notify Kissei when Inspire becomes
aware of any infringement action involving the Product in any country outside
the Territory in a timely manner.

          (b) Kissei shall have the first right, but not the duty, to institute
patent infringement actions against Third Parties based on any Licensed
Technology in the Territory.  If Kissei does not secure actual cessation of such
infringement or institute an infringement proceeding against an offending Third
Party within 180 days of learning of such infringement, Inspire shall have the
right, but not the duty, to institute such an action with respect to any
infringement by such Third Party.  The costs and expenses of any such action
(including fees of attorneys and other professionals) shall be borne by the
Party instituting the action, or, if the Parties elect to cooperate in
instituting and maintaining such action, such costs and expenses shall be borne
by the Parties in such proportions as they may agree in writing.  Each Party
shall execute all necessary and proper documents and take such actions as shall
be appropriate to allow the other Party to institute and prosecute such
infringement actions.  Any award paid by Third Parties as a result of such an
infringement action (whether by way of settlement or otherwise) shall be applied
first to reimburse both Parties for all costs and expenses incurred by the
Parties with respect to such action on a pro rata basis and, if after such
reimbursement any funds shall remain from such award, [CONFIDENTIAL TREATMENT
REQUESTED].

     9.4  Infringement Action by Third Parties.    In the event of the
institution or threatened institution of any suit by a Third Party against
Kissei for patent infringement involving the sale, distribution or marketing of
any Product in the Territory where such infringement claim is a result of the
use of the Licensed Technology, Kissei shall promptly notify Inspire in writing
of such suit.  Unless otherwise covered by Section 11.2(c), Kissei shall have
the right to defend such suit at its own expense,

                                      -28-
<PAGE>

and Inspire hereby agrees to assist and cooperate with Kissei, at Inspire's own
expense, to the extent necessary in the defense of such suit.  During the
pendency of such action and thereafter, Kissei shall continue to make all
payments due under this Agreement; provided, however, that Kissei shall be
entitled to a credit against royalties otherwise owing on such Product in an
amount equal to [CONFIDENTIAL TREATMENT REQUESTED] of the royalties or other
damages due to such Third Party in any calendar quarter, except that in no event
shall any such credit reduce the royalty rate to less than [CONFIDENTIAL
TREATMENT REQUESTED].  Further, if Kissei finally prevails and receives an award
from such Third Party as a result of such action (whether by way of judgment,
award, decree, settlement or otherwise), such award shall be allocated in the
manner provided in Section 9.3(b).

10.  PUBLICATION; CONFIDENTIALITY.

     10.1  Notification.

          (a) Both Parties recognize that each may wish to publish the results
of their work relating to the subject matter of this Agreement.  However, both
Parties also recognize the importance of acquiring patent protection.
Consequently, subject to any applicable laws or regulations obligating either
Party to do otherwise, any proposed publication by either Party shall comply
with this Section 10.1(a).  At least 30 days before a manuscript is to be
submitted to a publisher, the publishing Party will provide the Joint
Development Committee with a copy of the manuscript.  Any such manuscript, if
not in English, shall be accompanied by an English language  summary thereof,
which shall include a translation of all data tables to be included in such
manuscript.  In such event, the publishing Party shall provide an English
translation of such manuscript, in whole or in part, as requested by any member
of the Joint Development Committee, at least 10 days prior to submission of such
manuscript to the publisher.  If the publishing Party wishes to make an oral
presentation, it will provide the Joint Development Committee with a copy of the
abstract (if one is submitted) at least 30 days before it is to be submitted.

          (b) In addition, Inspire shall provide Kissei with a copy of any
publications relating to the Compound or the Product published by any of
Inspire's Strategic Partners in a timely manner after such publication.

     10.2  Review.    The Joint Development Committee will review the
manuscript, abstract, text or any other material provided under Section 10.1(a)
to determine whether patentable subject matter is disclosed.  The Joint
Development Committee will notify the publishing Party within 30 days of receipt
of the proposed publication if the Joint Development Committee, in good faith,
determines that patentable subject matter is or may be disclosed, or if the
Joint Development Committee, in good faith, believes Confidential Information
(as defined in Section 10.4) is or may be disclosed.  If it is determined by the
Joint Development Committee that patent applications should be filed, the
publishing Party shall delay its publication or presentation for a period not to
exceed 90 days from the Joint Development Committee's receipt of the proposed
publication or presentation to allow time for the filing of patent applications
covering patentable subject matter.  In the event that the delay

                                      -29-
<PAGE>

needed to complete the filing of any necessary patent application will exceed
the 90 day period, the Joint Development Committee will discuss the need for
obtaining an extension of the publication delay beyond the 90 day period. If it
is determined in good faith by the Joint Development Committee that Confidential
Information or proprietary information is being disclosed, the Parties will
consult in good faith to arrive at an agreement on mutually acceptable
modifications to the proposed publication or presentation to avoid such
disclosure.

     10.3  Exclusions.    Nothing in Sections 10.1 and 10.2 shall prevent either
Party: (i) in connection with efforts to secure financing at any time during the
term of this Agreement, from issuing statements as to achievements made, and the
status of the work being done by the Parties, under this Agreement, so long as
such statements do not jeopardize the ability to obtain patent protection on
Inventions or disclose non-public technical or scientific Confidential
Information; or (ii) from issuing statements that such Party determines to be
necessary to comply with applicable law (including the disclosure requirements
of the U.S. Securities and Exchange Commission, Nasdaq or any other stock
exchange on which securities issued by such Party are traded); provided that, to
the extent practicable under the circumstances, such Party shall provide the
other Party with a copy of the proposed text of such statements sufficiently in
advance of the scheduled release thereof to afford such other Party a reasonable
opportunity to review and comment upon the proposed text.

     10.4  Confidentiality; Exceptions.    Except to the extent expressly
authorized by this Agreement or otherwise agreed in writing, the Parties agree
that, during the term of this Agreement and for five years thereafter, the
receiving Party, its Affiliates, its licensees and its sublicensees shall keep,
and shall ensure that its employees, officers and directors keep, completely
confidential and shall not publish or otherwise disclose and shall not use for
any purpose any information furnished to it by the other Party, its Affiliates,
its licensees or its sublicensees or developed under or in connection with this
Agreement, except to the extent that it can be established by the receiving
Party by competent proof that such information: (i) was already known to the
receiving Party, other than under an obligation of confidentiality, at the time
of disclosure by the other Party; (ii) was generally available to the public or
otherwise part of the public domain at the time of its disclosure to the
receiving Party; (iii) became generally available to the public or was otherwise
part of the public domain after its disclosure and other than through any act or
omission of the receiving Party in breach of this Agreement; or (iv) was
disclosed to the receiving Party, other than under an obligation of
confidentiality,  by a Third Party who had no obligation to the disclosing Party
not to disclose such information to others  (all such information to which none
of the foregoing exceptions applies, "Confidential Information").

     10.5  Exceptions to Obligation.    The restrictions contained in Section
10.4 shall not apply to Confidential Information that: (i) is submitted by the
recipient to governmental authorities to facilitate the issuance of NDA
Approvals for the Product, provided that reasonable measures shall be taken to
assure confidential treatment of such information; (ii) is provided by the
recipient to Third Parties under confidentiality provisions at least as
stringent as those in this Agreement, for consulting, manufacturing development,
manufacturing, external testing, marketing trials and, with

                                      -30-
<PAGE>

respect to Kissei, to Third Parties who are Sublicensees or other
development/marketing partners of Kissei with respect to any of the subject
matter of this Agreement; or (iii) is otherwise required to be disclosed in
compliance with applicable laws or regulations or order by a court or other
regulatory body having competent jurisdiction; provided that if a Party is
required to make any such disclosure of the other Party's Confidential
Information such Party will, except where impracticable for necessary
disclosures, for example to physicians conducting studies or to health
authorities, give reasonable advance notice to the other Party of such
disclosure requirement and, except to the extent inappropriate in the case of
patent applications, will use its best efforts to secure confidential treatment
of such Confidential Information required to be disclosed.

     10.6  Limitations on Use.    Each Party shall use, and cause each of its
Affiliates, its licensees and its sublicensees to use, any Confidential
Information obtained by such Party from the other Party, its Affiliates, its
licensees or its sublicensees, pursuant to this Agreement or otherwise, solely
in connection with the activities or transactions contemplated hereby.

     10.7  Remedies.    Each Party shall be entitled, in addition to any other
right or remedy it may have, at law or in equity, to an injunction, without the
posting of any bond or other security, enjoining or restraining the other Party,
its Affiliates, its licensees and/or its sublicensees from any violation or
threatened violation of this Section 10.

11.  INDEMNIFICATION.

     11.1  By Kissei.    Kissei shall indemnify, defend and hold harmless
Inspire and its Affiliates, and their respective directors, officers, employees
and agents, from and against any and all liabilities, damages, losses, costs and
expenses (including the reasonable fees of attorneys and other professionals)
arising out of or resulting from:

          (a)  negligence, recklessness or wrongful intentional acts or
omissions of Kissei, its Affiliates or its Sublicensees, if any, and their
respective directors, officers, employees and agents, in connection with the
work performed by Kissei under the Joint Development Program;

          (b)  any warranty claims, Product recalls or any tort claims of
personal injury (including death) or property damage relating to or arising out
of any manufacture, use, distribution or sale of any Product by Kissei, its
Affiliates or its Sublicensees due to any negligence, recklessness or wrongful
intentional acts or omissions by, or strict liability of, Kissei, its Affiliates
or its Sublicensees, and their respective directors, officers, employees and
agents, except, in each case, to the comparative extent such claim arose out of
or resulted from the negligence, recklessness or wrongful intentional acts or
omissions of Inspire and its Affiliates, and their respective directors,
officers, employees and agents; or

                                      -31-
<PAGE>

          (c) any breach of any representation or warranty made by Kissei
pursuant to Section 2.

     11.2  By Inspire.    Inspire shall indemnify, defend and hold harmless
Kissei, its Affiliates and its Sublicensees, and their respective directors,
officers, employees and agents, from and against any and all liabilities,
damages, losses, costs and expenses (including the reasonable fees of attorneys
and other professionals) arising out of or resulting from:

          (a)  negligence, recklessness or wrongful intentional acts or
omissions of Inspire or its Affiliates, and their respective directors,
officers, employees and agents, in connection with the work performed by Inspire
under the Joint Development Program;

          (b)  any warranty claims, Product recalls or any tort claims of
personal injury (including death) or property damage relating to or arising out
of any manufacture, use, distribution or sale of any Supplied Goods by Inspire
or its Affiliates due to any negligence, recklessness or wrongful intentional
acts or omissions by, or strict liability of, Inspire or its Affiliates, and
their respective directors, officers, employees and agents, except, in each
case, to the comparative extent such claim arose out of or resulted from the
negligence, recklessness or wrongful intentional acts or omissions of Kissei,
its Affiliates or its Sublicensees, and their respective directors, officers,
employees and agents; or

          (c)  any breach of any representation or warranty made by Inspire
pursuant to Section 2.

     11.3  Notice.    In the event that any person (an "indemnitee") entitled to
indemnification under Section 11.1 or 11.2 is seeking such indemnification, such
indemnitee shall inform the indemnifying Party of the claim as soon as
reasonably practicable after such indemnitee receives notice of such claim,
shall permit the indemnifying Party to assume direction and control of the
defense of the claim (including the sole right to settle it at the sole
discretion of the indemnifying Party, provided that such settlement does not
impose any obligation on the indemnitee or the other Party) and shall cooperate
as requested (at the expense of the indemnifying Party) in the defense of the
claim.

     11.4  Complete Indemnification.    As the Parties intend complete
indemnification, all costs and expenses incurred by an indemnitee in connection
with enforcement of this Section 11 shall also be reimbursed by the indemnifying
Party.

12.  TERM; TERMINATION.

     12.1  Term.    This Agreement shall become effective as of the Effective
Date and, unless earlier terminated pursuant to the other provisions of this
Section 12, shall expire as follows:

                                      -32-
<PAGE>

          (a)  As to each Product in the Territory, this Agreement shall expire
on the later of  (i) the tenth anniversary of the First Commercial Sale of such
Product in the Territory, or (ii) the date on which the sale of such Product
ceases to be covered by a Licensed Claim in the Territory.

          (b)  This Agreement shall expire in its entirety upon the expiration
of this Agreement with respect to all Products in the Territory.

     12.2  Termination for Cause.    Either Party (the "non-breaching Party")
may, without prejudice to any other remedies available to it at law or in
equity, terminate this Agreement in the event the other Party (the "breaching
Party") shall have materially breached or defaulted in the performance of any of
its material obligations hereunder (but excluding any such breach or default
under the Supply Agreement, which shall be addressed in such separate Supply
Agreement), and such default shall have continued for 60 days after written
notice thereof was provided to the breaching party by the non-breaching party
(or, if such default cannot be cured within such 60-day period, if the breaching
party does not commence and diligently continue actions to cure such default
during such 60-day period).  Any such termination shall become effective at the
end of such 60-day period unless the breaching party has cured any such breach
or default prior to the expiration of such 60-day period (or, if such default
cannot be cured within such 60-day period, if the breaching party has commenced
and diligently continued actions to cure such default).  The right of either
party to terminate this Agreement as provided in this Section 12.2 shall not be
affected in any way by its waiver or failure to take action with respect to any
previous default.

     12.3  Termination by Kissei.    In the event that Kissei, in its sole good
faith discretion, determines that continued development or marketing of the
Product pursuant to this Agreement is scientifically or economically infeasible,
Kissei shall have the right to terminate this Agreement in its entirety upon
three months' prior written notice.

     12.4  Effect of Expiration or Termination.

          (a)  Following the expiration of the term of this Agreement with
respect to a Product in the Territory pursuant to Section 12.1(a):

          (i)  Kissei shall have a non-exclusive, royalty-free, perpetual right
to continue to use, market, distribute, sell, manufacture and have manufactured
any Product in the Territory, and the non-exclusive, perpetual and paid-up right
to use the Licensed Technology in connection therewith.  To that end, Kissei may
continue to hold and use all data, reports, records and materials that relate to
or are prepared in the course of the Joint Development Program, and may hold all
INDs, NDAs, NDA Approvals and other regulatory filings made or filed by Kissei
for such Product, pursuant to this Agreement, and may in its sole discretion
continue any sublicense granted by Kissei under this Agreement; and

                                      -33-
<PAGE>

          (ii)  Inspire shall have the fully-paid non-exclusive right to
continue to cross-reference and otherwise exercise its rights as set forth in
Section 4.5(d) under the NDA Approval(s) and other regulatory filings for such
Product in the Territory.

          (b)  Following expiration of the term of this Agreement in its
entirety pursuant to Section 12.1(b):

          (i)  Kissei shall have a non-exclusive, royalty-free, perpetual right
to continue to use, market, distribute, sell manufacture and have manufactured
all Products in the Territory, and the non-exclusive, perpetual and paid-up
right to use the Licensed Technology in connection therewith.  To that end,
Kissei may continue to hold and use all data, reports, records and materials
that relate to or are prepared in the course of the Joint Development Program,
and may hold all INDs, NDAs, NDA Approvals and other regulatory filings made or
filed by Kissei for all Products, pursuant to this Agreement, and may in its
sole discretion continue any sublicense granted by Kissei under this Agreement;

          (ii)  Inspire shall have: (A) the fully-paid non-exclusive right to
continue to cross-reference and otherwise exercise its rights as set forth in
Section 4.5(d) under the NDA Approvals and other regulatory filings for Products
in such countries; and (B) the fully-paid, non-exclusive, perpetual right to
continue to use patents or know-how that embody or relate to Inventions and that
are owned or controlled by Kissei or its Affiliates as set forth in Section 5.4.

          (c)  If this Agreement is terminated by Inspire pursuant to Section
12.2 by reason of a breach or default by Kissei, in addition to any other
remedies available to Inspire at law or in equity, or by Kissei pursuant to
Section 12.3: (i) Kissei shall promptly transfer to Inspire copies of all data,
reports, records and materials in Kissei's possession or control that relate to
the Joint Development Program and return to Inspire all relevant records and
materials in Kissei's possession or control containing Confidential Information
of Inspire (provided that Kissei may keep one copy of such Confidential
Information of Inspire for archival purposes only); (ii) all licenses granted by
Inspire to Kissei under Sections 5.1 and 5.2 shall terminate; (iii) ownership of
all INDs, NDAs, NDA Approvals and other regulatory filings made or filed for the
Product shall be transferred promptly to Inspire; and (iv) all sublicenses
granted by Kissei under this Agreement shall terminate.  Furthermore, Inspire
shall have the fully-paid, non-exclusive, perpetual right to continue to use
patents or know-how that embody or relate to Inventions and that are owned or
controlled by Kissei or its Affiliates as set forth in Section 5.4.

          (d)  If this Agreement is terminated by Kissei pursuant to Section
12.2 by reason of a breach or default by Inspire, in addition to any other
remedies available to Kissei at law or in equity,:  (i) the license granted to
Inspire by Kissei under Section 5.4 shall terminate; (ii) Kissei shall have an
exclusive, royalty-free, perpetual right to continue to use, market, distribute,
sell, manufacture and have manufactured any Product in the Territory, and the
exclusive, perpetual and paid-up right to use the Licensed Technology in
connection therewith.  To that end, Kissei may

                                      -34-
<PAGE>

continue to hold and use all data, reports, records and materials that relate to
or are prepared in the course of the Joint Development Program, and may hold all
INDs, NDAs, NDA Approvals and other regulatory filings made or filed by Kissei
for the Products, pursuant to this Agreement, and may in its sole discretion
continue any sublicenses granted by Kissei under this Agreement; and (iii) in
order to secure the right of Kissei in clause (ii) of this Section 12.4(d),
Inspire hereby grants Kissei the Manufacturing License as provided in the Supply
Agreement, and will use all reasonable efforts to enable Kissei to manufacture,
or have manufactured Finished Product and Delivery Systems, including working
with Kissei to establish arrangements with the Third Party Manufacturers.

     12.5  Accrued Rights; Surviving Obligations.

          (a)  Termination, relinquishment or expiration of this Agreement for
any reason shall be without prejudice to any rights which shall have accrued to
the benefit of either Party prior to such termination, relinquishment or
expiration.  Such termination, relinquishment or expiration shall not relieve
either Party from obligations which are expressly indicated to survive
termination or expiration of this Agreement.

          (b)  All of the Parties' rights and obligations under Sections 3.7,
4.7(d), 4.7(e), 4.8, 5.7, 7, 9.1, 9.3 (solely with respect to actions commenced
before the effective date of termination of this Agreement), 9.4 (solely with
respect to actions commenced before the effective date of termination of this
Agreement), 10.4, 10.5, 10.6, 10.7, 11, 12.4, 12.5, 14.12 and 14.13 shall
survive termination, relinquishment or expiration of this Agreement.

13.  FORCE MAJEURE.

     13.1  Events of Force Majeure.    Neither Party shall be held liable or
responsible to the other Party nor be deemed to be in default under, or in
breach of any provision of, this Agreement for failure or delay in fulfilling or
performing any obligation of this Agreement when such failure or delay is due to
force majeure, and without the fault or negligence of the Party so failing or
delaying.  For purposes of this Agreement, force majeure is defined as causes
beyond the control of the Party, including, without limitation, acts of God;
acts, regulations, or laws of any government; war; civil commotion; destruction
of production facilities or materials by fire, flood, earthquake, explosion or
storm; labor disturbances; epidemic; and failure of public utilities or common
carriers.  In such event Inspire or Kissei, as the case may be, shall
immediately notify the other Party of such inability and of the period for which
such inability is expected to continue.  The Party giving such notice shall
thereupon be excused from such of its obligations under this Agreement as it is
thereby disabled from performing for so long as it is so disabled and the 30
days thereafter.  To the extent possible, each Party shall use reasonable
efforts to minimize the duration of any force majeure.

                                      -35-
<PAGE>

14.  MISCELLANEOUS.

     14.1  Relationship of Parties.    Nothing in this Agreement is intended or
shall be deemed to constitute a partnership, agency, employer-employee or joint
venture relationship between the Parties.  No Party shall incur any debts or
make any commitments for the other, except to the extent, if at all,
specifically provided herein.

     14.2  Assignment.    Neither Party shall be entitled to assign its rights
hereunder without the express written consent of the other Party hereto, except
that each Party may assign its rights and transfer its duties hereunder to any
assignee of all or substantially all of its business (or that portion thereof to
which this Agreement relates) or in the event of such Party's merger,
consolidation or involvement in a similar transaction.  No assignment and
transfer shall be valid or effective unless done in accordance with this Section
14.2 and unless and until the assignee/transferee shall agree in writing to be
bound by the provisions of this Agreement.

     14.3  Books and Records.    Any books and records to be maintained under
this Agreement by a Party or its Affiliates or Sublicensees shall be maintained
in accordance with generally accepted accounting principles, consistently
applied.

     14.4  Further Actions.    Each Party shall execute, acknowledge and deliver
such further instruments, and do all such other acts, as may be necessary or
appropriate in order to carry out the purposes and intent of this Agreement.

     14.5  Notice.

          (a)  Any notice or request required or permitted to be given under or
in connection with this Agreement shall be deemed to have been sufficiently
given if in writing and personally delivered or sent by certified mail (return
receipt requested), facsimile transmission (receipt verified), or overnight
express courier service (signature required), prepaid, to the Party for which
such notice is intended, at the address set forth for such Party below:

               (i)  In the case of Inspire, to:

                    Inspire Pharmaceuticals, Inc.
                    4222 Emperor Boulevard, Suite 470
                    Durham, North Carolina  27703
                    USA
                    Attention: Christy L. Shaffer, Ph.D.
                    Facsimile No.:  (919) 941-9797

                                      -36-
<PAGE>

               (ii) In the case of Kissei, to:

                    Kissei Pharmaceutical Co., Ltd.
                    19-48, Yoshino
                    Matsumoto-City, Nagano-Prefecture
                    399-8710
                    JAPAN
                    Attention: Masanori Iwadare, Ph.D.
                    Facsimile No.:  (263) 28-2174

or to such other address for such Party as it shall have specified by like
notice to the other Party, provided that notices of a change of address shall be
effective only upon receipt thereof.  If delivered personally or by facsimile
transmission, the date of delivery shall be deemed to be the date on which such
notice or request was given.  If sent by overnight express courier service, the
date of delivery shall be deemed to be the next business day after such notice
or request was deposited with such service.  If sent by certified mail, the date
of delivery shall be deemed to be the third business day after such notice or
request was deposited with the U.S. or Japanese Postal Service, as the case may
be.

          (b)  All correspondence, notices and other communications shall be
promptly provided to the other Party in English.  If any data, information and
document or literature which relate to Joint Development Program or any
regulatory filings is written in non-English language, an appropriate summary in
English shall be attached to it, and an English translation will follow in a
timely manner if requested.

     14.6  Use of Name.    Except as otherwise provided herein, neither Party
shall have any right, express or implied, to use in any manner the name or other
designation of the other Party or any other trade name or trademark of the other
Party for any purpose in connection with the performance of this Agreement.

     14.7  Public Announcements.    Except as required by law (including,
without limitation, disclosure requirements of the U.S. Securities and Exchange
Commission, Nasdaq or any other stock exchange on which securities issued by a
Party are traded) and as permitted by Section 10.3, neither Party shall make any
public announcement concerning this Agreement or the subject matter hereof
without the prior written consent of the other, which shall not be unreasonably
withheld, provided that it shall not be unreasonable for a Party to withhold
consent with respect to any public announcement containing any of such Party's
Confidential Information.  In the event of a required public announcement, to
the extent practicable under the circumstances, the Party making such
announcement shall provide the other Party with a copy of the proposed text
prior to such announcement sufficiently in advance of the scheduled release of
such announcement to afford such other Party a reasonable opportunity to review
and comment upon the proposed text.

                                      -37-
<PAGE>

     14.8  Waiver.    A waiver by either Party of any of the terms and
conditions of this Agreement in any instance shall not be deemed or construed to
be a waiver of such term or condition for the future, or of any subsequent
breach hereof.  All rights, remedies, undertakings, obligations and agreements
contained in this Agreement shall be cumulative and none of them shall be in
limitation of any other remedy, right, undertaking, obligation or agreement of
either Party.

     14.9  Compliance with Law.    Nothing in this Agreement shall be deemed to
permit a Party to export, reexport or otherwise transfer any Product sold under
this Agreement without compliance with applicable laws.

     14.10  Severability.    When possible, each provision of this Agreement
will be interpreted in such manner as to be effective and valid under applicable
law, but if any provision of this Agreement is held to be prohibited by or
invalid under applicable law, such provision will be ineffective only to the
extent of such prohibition or invalidity, without invalidating the remainder of
this Agreement.

     14.11  Amendment.    No amendment, modification or supplement of any
provisions of this Agreement shall be valid or effective unless made in writing
and signed by a duly authorized officer of each Party.

     14.12  Governing Law; English Original Controlling.    This Agreement shall
be governed by and interpreted in accordance with the laws of Delaware without
regard to its choice of law principles; provided, however, that any arbitration
proceeding conducted pursuant to Section 14.13 shall be governed by the
Convention on the Recognition and Enforcement of Foreign Arbitral Awards of June
10, 1958.  The English original of this Agreement shall prevail over any
translation hereof.

     14.13  Arbitration.

          (a)  Except as expressly otherwise provided in this Agreement, any
dispute arising out of or relating to any provisions of this Agreement shall be
finally settled by arbitration to be held in San Francisco, California, under
the auspices and then current commercial arbitration rules of the International
Chamber of Commerce.  Such arbitration shall be conducted by three arbitrators
appointed according to said rules and in the English language.  The Parties
shall instruct such arbitrators to render a determination of any such dispute
within 30 days after their appointment.

          (b)  Any award rendered by the arbitrator(s) shall be final and
binding upon the Parties.  Judgment upon any award rendered may be entered in
any court having jurisdiction, or application may be made to such court for a
judicial acceptance of the award and an order of enforcement, as the case may
be.  Each Party shall pay its own expenses of arbitration, and the expenses of
the arbitrator(s) shall be equally shared unless the arbitrator(s) assesses as
part of his or

                                      -38-
<PAGE>

her award all or any part of the arbitration expenses of one Party (including
reasonable attorneys' fees) against the other Party.

          (c)  This Section 14.13 shall not prohibit a Party from seeking
injunctive relief from a court of competent jurisdiction in the event of a
breach or prospective breach of this Agreement by the other Party which would
cause irreparable harm to the first Party.

     14.14  Entire Agreement.    This Agreement, together with the Exhibits
hereto and every Annual Development Plan approved by the Joint Development
Committee, sets forth the entire agreement and understanding between the Parties
as to the subject matter hereof and merges all prior discussions and
negotiations between them, and neither of the Parties shall be bound by any
conditions, definitions, warranties, understandings or representations with
respect to such subject matter other than as expressly provided herein or as
duly set forth on or subsequent to the date hereof in writing and signed by a
proper and duly authorized officer or representative of the Party to be bound
thereby.

     14.15  Parties in Interest.    All of the terms and provisions of this
Agreement shall be binding upon, inure to the benefit of and be enforceable by
the Parties hereto and their respective permitted successors and assigns.

     14.16  Descriptive Headings.    The descriptive headings of this Agreement
are for convenience only, and shall be of no force or effect in construing or
interpreting any of the provisions of this Agreement.

     14.17  Counterparts.    This Agreement may be executed simultaneously in
any number of counterparts, any one of which need not contain the signature of
more than one Party but all such counterparts taken together shall constitute
one and the same agreement.

                                     * * *

                                      -39-
<PAGE>

     IN WITNESS WHEREOF, each of the Parties has caused this Agreement to be
executed by its duly authorized representative as of the day and year first
above written.

                                    INSPIRE PHARMACEUTICALS, INC.

                                    By: /s/ David J. Drutz
                                        -----------------------------------
                                        David J. Drutz, M.D., Vice Chairman

                                    KISSEI PHARMACEUTICALS CO., LTD.

                                    By:/s/ Mutsuo Kanzawa
                                       -------------------------------
                                        Mutsuo Kanzawa, President and
                                         Chief Executive Officer
<PAGE>

                                                                       EXHIBIT A
                                                                       ---------

                                INSPIRE'S COSTS
                                ---------------

The terms (1) Cost of Compound, (2) Cost of Formulated Material, (3) Cost of
Finished Product, and (4) Cost of Delivery Systems, shall be determined, in
accordance with generally accepted accounting principles in the United States
consistently applied, as follows:

1.   "Cost of Compound" shall mean the purchase unit costs incurred by Inspire
     in connection with the

     [CONFIDENTIAL TREATMENT REQUESTED]

2.   "Cost of Formulated Material" shall mean the purchase unit costs incurred
     by Inspire in connection with the

     [CONFIDENTIAL TREATMENT REQUESTED]

3.   "Cost of Finished Product" shall mean the purchase unit costs incurred by
     Inspire in connection with the

     [CONFIDENTIAL TREATMENT REQUESTED]

4.   "Cost of Delivery Systems" shall mean the purchase unit costs incurred by
     Inspire in connection with the

     [CONFIDENTIAL TREATMENT REQUESTED]

For purposes of the calculation of Inspire's Costs under this Agreement,
"Related Third Party Costs" shall mean all other Third Party costs incurred by
Inspire in connection with the
[CONFIDENTIAL TREATMENT REQUESTED]

For purposes of this Exhibit A, Kissei's pro rata share of any extraordinary
expenses shall be calculated by multiplying the amount of such extraordinary
expenses charged by Third Parties during a particular time period by a fraction,
the numerator of which is the [CONFIDENTIAL TREATMENT REQUESTED] during such
period and the denominator of which is the aggregate amount of [CONFIDENTIAL
TREATMENT REQUESTED].<PAGE>

                              DEVELOPMENT, LICENSE
                              AND SUPPLY AGREEMENT

     THIS DEVELOPMENT, LICENSE AND SUPPLY AGREEMENT (this "Agreement"), dated as
of December 16, 1998, is entered into by and between Inspire Pharmaceuticals,
Inc., a corporation organized and existing under the laws of the State of
Delaware, having offices located at 4222 Emperor Boulevard, Suite 470, Durham,
North Carolina 27703, USA ("Inspire"), and Santen Pharmaceutical Co., Ltd., a
corporation organized under the laws of Japan, having offices located at 3-9-19
Shimoshinjo, Higashiyodogawa-ku, Osaka, 533-8651, Japan ("Santen").

                             PRELIMINARY STATEMENTS
                             ----------------------

     A.  Inspire owns, and/or has exclusive rights to, the Patents and Know-How
in existence as of the Effective Date relating to the Compound.

     B.  Santen has the personnel, facilities and expertise necessary for the
development and commercialization of the Product in the Territory.

     C. Santen wishes to develop and commercialize the Product in the Territory,
and Inspire wishes to have Santen do so, upon the terms and conditions set forth
in this Agreement. In connection therewith, Santen desires to obtain, and
Inspire desires to grant to Santen, an exclusive license under the Licensed
Technology with respect to the commercialization of the Product in the Territory
for applications in the Field, subject to Inspire's right to manufacture and
supply Compound for Santen, all on the terms and conditions set forth below.

     D. Simultaneously with the execution of this Agreement, the Parties are
entering in that certain Stock Purchase Agreement (the "Stock Purchase
Agreement") and the documents ancillary thereto, all dated of even date
herewith, pursuant to which Santen is purchasing shares of Series D Preferred
Stock of Inspire.

     NOW, THEREFORE, in consideration of the foregoing Preliminary Statements
and the mutual agreements and covenants set forth herein, the Parties hereby
agree as follows:

1.   DEFINITIONS.

     As used in this Agreement, the following terms shall have the meanings set
forth in this Section 1 unless context dictates otherwise:

     1.1 "Affiliate," with respect to any Party, shall mean any entity
controlling, controlled by, or under common control with, such Party. For these
purposes, "control" shall refer to: (i) the possession, directly or indirectly,
of the power to direct the management or policies of an entity, whether through
the ownership of voting securities, by contract or otherwise, or (ii) the
ownership, directly or indirectly, of at least 50% of the voting securities or
other ownership interest of an entity.
<PAGE>

     1.2 "cGMP" shall mean current Good Manufacturing Practice as defined in
Parts 210 and 211 of Title 21 of the U.S. Code of Federal Regulations, as may be
amended from time to time, or any successor thereto.

     1.3 "Compound" shall mean the chemical compound designated as INS365, whose
chemical name is P1, P4-Di(uridine 5'-tetraphosphate), and all sodium salts
thereof.

     1.4 "Compound Specifications" shall mean the specifications for the
Compound agreed upon by the Parties, in accordance with Section 8.1(c), in
consideration of the regulatory requirements in each country in the Territory,
as may be amended from time to time.

     1.5 "Confidential Information" shall have the meaning assigned to such term
in Section 10.4.

     1.6 "Coordinating Committee" shall have the meaning assigned to such term
in Section 3.1.

     1.7 "Cost of Compound" shall mean Inspire's fully burdened costs associated
with the manufacture of the Compound, as determined pursuant to Exhibit A.

     1.8 "Development Program" shall mean the development program with respect
to the Product conducted by Santen to obtain Registration of the Product in each
country in the Territory pursuant to Section 4.

     1.9  "Effective Date" shall mean the date of this Agreement.

     1.10 "Executive Officers" shall have the meaning assigned to such term in
Section 3.2(b).

     1.11 "Field" shall mean the therapeutic treatment of ocular surface
diseases (including dry eye, regardless of how caused) in humans.

     1.12 "First Commercial Sale" shall mean the first sale for use or
consumption by the general public of the Product in any country in the Territory
after all required Registrations have been granted, or such sale is otherwise
permitted, by the Regulatory Authority in such country.

     1.13 "Generic Product" shall mean, on a country-by-country basis, the
ophthalmic formulation of any product for use in the Field that contains the
Compound as an active ingredient: (i) the manufacture, use or sale of which is
not covered by a Licensed Claim in such country, and (ii) [CONFIDENTIAL
TREATMENT REQUESTED].

                                      -2-
<PAGE>

     1.14 "IND" shall mean any filing made with the Regulatory Authority in any
country in the Territory for initiating clinical trials in such country with
respect to the Product.

     1.15 "Invention" shall mean any new or useful process, manufacture,
compound or composition of matter relating to the Compound or the Product
(including, without limitation, the formulation, delivery or use thereof),
whether patentable or unpatentable, or any improvement thereof, that is
conceived or first reduced to practice or demonstrated to have utility during
the term of this Agreement.

     1.16 "Know-how" shall mean any and all Inventions, improvements,
discoveries, claims, formulae, processes, trade secrets, technologies and know-
how (including confidential data and Confidential Information) that is
generated, owned or controlled by Inspire at any time before or during the term
of this Agreement relating to, derived from or useful for the use or sale of the
Compound or the Product, including, without limitation, synthesis, preparation,
recovery and purification processes and techniques, control methods and assays,
chemical data, toxicological and pharmacological data and techniques, clinical
data, medical uses, product forms and product formulations and specifications.

     1.17 "Licensed Claim" shall mean any claim of any Patent that relates to
and is necessary for the use and sale of the Compound or the Product, which
claim has not been held invalid or unenforceable by decision of a court or other
governmental agency of competent jurisdiction, unappealable or unappealed within
the time allowed for appeal, and which is not admitted to be invalid through
disclaimer or otherwise not admitted by Inspire to be invalid.

     1.18  "Licensed Technology" shall mean the Licensed Claims and Know-how,
collectively.

     1.19 "Manufacturing Standards" shall mean, with respect to the Compound,
cGMP and such additional manufacturing specifications or standards as may be
established by mutual agreement of the Parties from time to time, in accordance
with Section 8.1(c).

     1.20 "Net Sales" shall mean, with respect to the Product, the gross amount
invoiced for the Product by Santen, its Affiliates and Sublicensees, if any, in
arm's length sales to Third Parties, commencing with the First Commercial Sale,
less deductions for: (i) trade, quantity and/or cash discounts, allowances and
rebates actually allowed or given; (ii) freight, postage, shipping insurance and
other transportation expenses (if separately identified in such invoice); (iii)
credits or refunds actually allowed for rejections, defects or recalls of such
Product, outdated or returned Product, or because of rebates or retroactive
price reductions; and (iv) sales, value-added, excise taxes, tariffs and duties,
and other taxes directly related to the sale, to the extent that such items are
included in the gross invoice price (but not including taxes assessed against
the income derived from such sale). Such amounts shall be determined from the
books and records maintained by Santen, its Affiliates or Sublicensees, as
applicable.

                                      -3-
<PAGE>

     1.21 "Party" shall mean Inspire or Santen and, when used in the plural,
shall mean Inspire and Santen.

     1.22 "Patents" shall mean the patents set forth on Exhibit B, and any other
patents or patent applications in the Territory owned or controlled by Inspire
during the term of this Agreement that relate to the Compound or the Product,
together with any patents that may issue therefor in the Territory, including
any and all extensions, renewals, continuations, continuations-in- part,
divisions, patents-of-additions, reissues, supplementary protection certificates
or foreign counterparts of any of the foregoing.

     1.23 "Product" shall mean all ophthalmic formulations of any product for
use in the Field that contains the Compound as an active ingredient, the
manufacture, use or sale of which either is: (i) based upon, derived from or
related to any of the Know-how; and/or (ii) covered by one or more Licensed
Claims and, but for this Agreement, would constitute an infringement (whether
directly, contributorily or by inducement) thereof.

     1.24 "Registration" shall mean, with respect to each country in the
Territory, approval of the Registration Application for the Product filed in
such country, including pricing or reimbursement, where applicable, by the
Regulatory Authority in such country.

     1.25 "Registration Application" shall mean any filing(s) made with the
Regulatory Authority in any country in the Territory for regulatory approval of
the manufacture and sale of the Product in such country.

     1.26 "Regulatory Authority" shall mean the authority(ies) in each country
in the Territory with responsibility for granting regulatory approval for the
manufacturing and sale of the Product in such country, and any successor(s)
thereto.

     1.27 "Stock Purchase Agreement" shall have the meaning assigned to such
term in the Preliminary Statements.

     1.28 "Strategic Partners" shall have the meaning assigned to such term in
Section 4.3(e).

     1.29 "Sublicensee" shall mean a Third Party to which Santen has granted a
sublicense to develop, manufacture, use or sell the Product in any country in
the Territory, pursuant to Section 5.3.

     1.30  "Territory" shall mean Japan, China, South Korea, the Philippines,
Thailand, Vietnam, Taiwan, Singapore, Malaysia and Indonesia.

     1.31 "Testing Methods" shall have the meaning assigned to such term in
Section 8.5(c).

     1.32 "Third Party" shall mean any person who or which is neither a Party
nor an Affiliate of a Party.

                                      -4-
<PAGE>

     1.33 "Third Party Manufacturer" shall have the meaning assigned to such
term in Section 8.7(a).

     1.34  "Trademark" shall have the meaning assigned thereto in Section 5.6.

     1.35 "Transfer Price" shall have the meaning assigned to such term in
Section 6.2.

2.   REPRESENTATIONS AND WARRANTIES.

     2.1  Representations and Warranties of Both Parties.    Each Party
represents and warrants to the other Party, as of the Effective Date, that:

          (a) such Party is duly organized, validly existing and in good
standing under the laws of the jurisdiction of its incorporation and has full
corporate power and authority to enter into this Agreement and to carry out the
provisions hereof;

          (b) such Party is free to enter into this Agreement;

          (c) in so doing, such Party will not violate any other agreement to
which it is a party;

          (d) such Party has taken all corporate action necessary to authorize
the execution and delivery of this Agreement and the performance of its
obligations under this Agreement; and

          (e) except as expressly provided in Section 2.2(e), no person or
entity has or will have, as a result of the transactions contemplated by this
Agreement, any right, interest or valid claim against or upon such Party for any
commission, fee or other compensation as a finder or broker because of any act
or omission by such Party or any of its agents.

     2.2  Representations and Warranties of Inspire. Inspire represents and
warrants to Santen, as of the Effective Date, that:

          (a) Inspire is the owner of, or has exclusive rights to, all of the
Patents in existence on the Effective Date, and has the exclusive right to grant
the licenses granted under this Agreement therefor;

          (b) to the best of Inspire's knowledge, Inspire has exclusive rights
to all of the Know-how in existence on the Effective Date and the exclusive
right to grant licenses with respect thereto;

                                      -5-
<PAGE>

          (c) to the best of Inspire's knowledge, Santen's use of the Compound
in the Field, in accordance with the terms of this Agreement, does not infringe
upon or conflict with any patent or other proprietary rights in the Territory of
any Third Party;

          (d) Inspire has not entered into any agreement with any Third Party
that is in conflict with the rights granted to Santen pursuant to this
Agreement; and

          (e) Pharma $ Logic Development, Inc. has acted as a consultant/broker
on behalf of Inspire with respect to the transactions contemplated by this
Agreement.  Inspire has paid, or will pay, Pharma $ Logic Development, Inc. all
fees and expenses due to it in connection herewith.

     2.3 Representations and Warranties of Santen . Santen represents and
warrants to Inspire, as of the Effective Date, that:

          (a) Santen has the facilities, personnel and experience sufficient in
quantity and quality to perform its obligations under this Agreement;

          (b) All of the personnel assigned to perform such obligations shall be
qualified and properly trained; and

          (c) Santen shall perform such obligations in a manner commensurate
with professional standards generally applicable in its industry.

3.   COORDINATING COMMITTEE.

     3.1 Members; Chairperson. The Parties shall establish a coordinating
committee (the "Coordinating Committee"), that shall consist of four to six
members, as the Parties may deem necessary from time to time, with an equal
number of members from each Party. At least one member from each Party must be a
product development professional. The Coordinating Committee shall initially
consist of six members, who are set forth on Exhibit C. A member of the
Coordinating Committee may be represented at any meeting by a designee appointed
by such member for such meeting. The chairperson of the Coordinating Committee
shall serve a one-year term, commencing on the Effective Date or an anniversary
thereof, as the case may be. The right to name the chairperson of the
Coordinating Committee shall alternate between the Parties, and each chairperson
shall be named no later than 10 days after the commencement of his or her term.
The initial chairperson shall be selected by Santen and is designated on Exhibit
C. Each Party shall be free to change its members, upon prior written notice to
the other Party. Each Party may, in its discretion, invite non-member
representatives of such Party to attend meetings of the Coordinating Committee,
provided that the other Party approves such Party's invitee(s) in advance.

                                      -6-
<PAGE>

     3.2 Responsibilities.

        (a) Subject to the other terms of this Agreement, the Coordinating
Committee shall review and evaluate the sufficiency of Santen's progress in the
development and commercialization of the Product in each country in the
Territory and shall provide input and recommendations regarding the development
of the Product. Without limiting the generality of the foregoing, the
Coordinating Committee shall:

           (i) review data and reports arising from and generated in connection
with the Development Program;

           (ii) review all proposed publications and presentations of the
Parties pursuant to Section 10.2;

           (iii) review all studies relating to the Product and any other
studies proposed to be performed in connection with the registration process for
the Product under this Agreement;

           (iv) provide a mechanism for the exchange of information between the
Parties with regard to Know-how and Inventions; and

           (v) have such other responsibilities as may be assigned to the
Coordinating Committee pursuant to this Agreement or as may be mutually agreed
upon by the Parties from time to time.

        (b) In the event that, after good faith discussions, the Coordinating
Committee cannot reach consensus regarding whether Santen shall have made
reasonably sufficient progress in the development and commercialization of the
Product in any country in the Territory, the matter shall be referred for
further review and resolution to an officer at the senior executive level at
Inspire, and an officer at the senior executive level at Santen (such officers
collectively, the "Executive Officers"). The Executive Officers shall use
reasonable efforts to resolve the matter within 30 days after the matter is
referred to them. If the Executive Officers are unable to reach a resolution of
the matter within this period of time, the matter shall be submitted to binding
arbitration in San Francisco, California, for arbitration pursuant to then
current commercial arbitration rules of the American Arbitration Association,
but otherwise pursuant to Section 14.13.

          (c) Although the Coordinating Committee shall provide its input and
recommendations regarding the development of the Product, Santen shall have the
sole control and discretion over the development of the Product in any manner
consistent with its obligations under this Agreement.

     3.3 Meetings. During the term of the Development Program and the 12-month
period thereafter, the Coordinating Committee shall meet at least twice during
every calendar year, and

                                      -7-
<PAGE>

more frequently as the Parties deem appropriate, on such dates, and at such
times and places, as the Parties shall agree; provided, however, that at least
one meeting during each calendar year shall be held in each of the United States
and Japan, unless the Parties otherwise agree. Thereafter, during the remainder
of the term of this Agreement, the Coordinating Committee shall meet on an as-
needed basis on such dates, and at such places and times, as the Parties shall
agree. The chairperson shall, if practicable, send notice of all meetings to all
members of the Coordinating Committee no less than 20 days before the date of
each meeting. The Coordinating Committee may also convene or be polled or
consulted from time to time by means of telecommunications, video conferences or
correspondence, as deemed necessary or appropriate; provided, however, that the
Coordinating Committee must meet in person at least twice every calendar year
during the term of the Development Program and the 12-month period thereafter.

     3.4 Term. The Coordinating Committee shall exist until the termination or
expiration of the Development Program and for such longer period as the Parties
may mutually agree (taking into consideration the responsibilities (e.g., review
of proposed publications) assigned to the Coordinating Committee under this
Agreement).

     3.5 Expenses. Each Party shall be responsible for all travel and related
costs and expenses for its members and approved invitees to attend meetings of,
and otherwise participate on, the Coordinating Committee.

4    DEVELOPMENT PROGRAM.

     4.1 Generally . Santen shall use all commercially reasonable efforts
diligently to develop and commercialize the Product in each country in the
Territory (including, without limitation, obtaining all Registrations necessary
to market and sell the Product in each such country), in such order of priority
as Santen reasonably shall deem appropriate. In connection therewith, Santen
shall dedicate resources to the development and commercialization of the Product
consistent with the resources that Santen, at all relevant times, would dedicate
to products containing compounds with similar indications and side effects
profiles to those of the Compound that were generated from Santen's own research
efforts and that Santen decided to develop commercially and market.

     4.2 Specific Santen Responsibilities. As part of the Development Program,
Santen shall:

        (a) Conduct, or cause to be conducted, manage and oversee any additional
pre-clinical pharmacological or toxicological studies, required by the
Regulatory Authorities in order to file a Registration Application for the
Product in each country in the Territory;

        (b) Conduct, or cause to be conducted, manage and oversee formulation of
the Product for use in clinical studies and for subsequent marketing;

                                      -8-
<PAGE>

           (c) Conduct, or cause to be conducted, manage and oversee all
clinical studies required by the Regulatory Authorities in order to obtain
Registration for the Product in each country in the Territory;

           (d) Make and pursue all regulatory filings (including, without
limitation, all INDs and Registration Applications), based in part on the
information and documentation provided by Inspire and in part on information and
data generated and obtained by Santen in connection with the Development
Program, and conduct all analysis and other support necessary with respect to
the manufacture and sale of the Product in the Territory;

           (e) Use all commercially reasonable efforts and proceed diligently to
perform such obligations, including, without limitation, by using personnel with
sufficient skills and experience, together with sufficient equipment and
facilities;

          (f) Conduct the Development Program in good scientific manner, and in
compliance in all material respects with all requirements of applicable laws,
rules and regulations, and all other requirements of any applicable current good
clinical practice, current good laboratory practice and current good
manufacturing practice to attempt to achieve the objectives of the Development
Program efficiently and expeditiously;

           (g) Within 30 days after the end of each six-month period during the
term of the Development Program and within 30 days following the expiration or
termination of the Development Program, furnish the Coordinating Committee with
reasonably detailed, written reports on all activities conducted by Santen under
the Development Program during such six-month period or the term of the
Development Program, as the case may be;

           (h) Maintain records, in sufficient detail and in good scientific
manner, which shall be complete and accurate and shall fully and properly
reflect all work done and results achieved in connection with the Development
Program in the form required under all applicable laws and regulations. Inspire
shall have the right, during normal business hours and upon reasonable notice,
to inspect and copy all such records. Inspire shall maintain such records and
information contained therein in confidence in accordance with Section 10 and
shall not use such records or information except to the extent otherwise
permitted by this Agreement; and

           (i) Allow representatives of Inspire, upon reasonable notice and
during normal business hours, to visit Santen's facilities where the Development
Program is being conducted, and consult informally, during such visits and by
telephone, with Santen's personnel performing work on the Development Program.

     4.3   Inspire Activities. In support of the Development Program, Inspire
shall:

          (a) Immediately after the Effective Date, provide to Santen copies of
all (or relevant portions of) primary and secondary pre-clinical
pharmacological, toxicological, formulation

                                      -9-
<PAGE>

and stability data, either in the Field or outside the Field but having utility
in the Field, relating to the development and commercialization of the Product,
in Inspire's possession and control (including, without limitation, such data,
studies and materials of Strategic Partners, to the extent Inspire has the right
to provide same to Santen);

          (b) Thereafter, provide to Santen copies of: (i) all primary and
secondary pre-clinical pharmacological, toxicological, formulation and stability
data, either in the Field or outside the Field but having utility in the Field,
relating to the development and commercialization of the Product, and (ii) all
preclinical data concerning the Field, that comes into Inspire's possession and
control during the term of this Agreement (including, without limitation, such
data, studies and materials of Strategic Partners, to the extent Inspire has the
right to provide same to Santen);

          (c) Supply Santen or its designee(s) with sufficient quantities of
Compound, manufactured in accordance with cGMP and the Compound Specifications,
to complete all pre-clinical and clinical studies and all development, analysis,
regulatory support, manufacturing and all other Registration-related activities
with respect to the Product in which Santen is required to engage by applicable
law or regulation until the commercial launch, or the affirmative decision of
Santen not to pursue the commercial launch, of the Product in each country in
the Territory. Such Compound shall be supplied to Santen at the Transfer Price
set forth in Section 6.2, and shall be paid as provided in Section 4.5(b). Such
Compound shall be supplied in accordance with quarterly forecasts therefor
provided by Santen at least 180 days prior to the anticipated delivery date for
each shipment of Compound. Santen shall have the right, at reasonable times and
upon reasonable notice, to inspect all facilities at which Compound is
manufactured pursuant to this Section 4.3(c) for compliance with cGMP;

          (d) Within 30 days after the end of each six-month period during the
term of the Development Program, furnish the Coordinating Committee with
reasonably detailed, written reports on all activities conducted by Inspire and
its Strategic Partners (to the extent Inspire has the right to provide such
information to Santen) during such six-month period in connection with the
development and commercialization of all products for respiratory indications
that contain the Compound as an active ingredient.

          (e) Negotiate in good faith with all of Inspire's other strategic
partners and/or licensees for the Compound (collectively, "Strategic Partners")
that are relevant to obtain the right: (i) to disclose to Santen all Third Party
data or information owned by such Strategic Partners that this Agreement
contemplates will be shared with Santen to the extent that Inspire has the right
to do so, and (ii) to grant Santen the right to cross-reference regulatory
filings owned by such Strategic Partners that this Agreement contemplates will
be granted to Santen to the extent that Inspire has the right to do so.

                                      -10-
<PAGE>

     4.4  Regulatory Matters.

          (a) Santen shall be responsible for preparing and filing INDs,
Registration Applications and other regulatory filings for the Product in each
country in the Territory through and including Registration, and thereafter
shall be responsible for maintaining such Registrations. All such filings shall
be in Santen's name (or that of its Affiliates, Sublicensees or distributors, as
the case may be). Santen shall also obtain any export approvals required by the
Regulatory Authorities to export Product among the countries of the Territory.

          (b) Santen or, where required by applicable law, its designees(s)
shall own all INDs, Registration Applications, Registrations and other
regulatory filings for the Product in each country in the Territory.

          (c) In order to assist Santen in the performance of its obligations
under this Section 4.4, Inspire shall provide Santen or its designee(s) with
complete copies (or copies of relevant portions) of, and shall grant Santen or
its designee(s) the right to cross-reference, all of Inspire's and its Strategic
Partners' (to the extent Inspire has the right to provide such information to
Santen) INDs, registration applications, registrations or other regulatory
filings made or held in any country for all products that contain the Compound
as an active ingredient. Inspire shall execute, acknowledge and deliver such
further instruments, and shall do all such other acts, all as promptly as
possible after Santen's request therefor, at Santen's expense, that may be
necessary or appropriate to effectuate such right.

          (d) Upon Inspire's written request, Santen shall provide Inspire with
complete copies (or copies of relevant portions) of, and shall grant Inspire the
right to cross-reference any INDs, Registration Applications, Registrations or
other regulatory filings made or held in each country in the Territory in the
name of Santen (or that of its Affiliates, Sublicensees or distributors, as the
case may be) reasonably necessary or useful to enable Inspire to market products
either within the Territory and outside the Field, or outside the Territory.
Santen shall not be obligated to provide English translations of such filings,
but shall provide any English translations made by Santen, in its sole
discretion, if requested by Inspire. Santen shall execute, acknowledge and
deliver such further instruments, and shall do all such other acts, all as
promptly as possible after Inspire's request therefor, at Inspire's expense,
that may be necessary or appropriate to effectuate such right in each such
country. Santen also shall provide such copies and such right to cross-
reference to any Strategic Partner that grants Santen or its designee(s) the
right to cross-reference such Strategic Partner's INDs, registration
applications, registrations or other regulatory filings made or held in any
country for products that contain the Compound as an active ingredient.

          (e) Santen shall keep Inspire informed as to the status of all
regulatory filings made pursuant to this Section 4.4.

          (f) In connection with any IND or Registration Application filed by
Santen pursuant to this Section 4.4, Santen shall notify Inspire as soon as
reasonably possible of any

                                      -11-
<PAGE>

meeting with the Regulatory Authority in any country in the Territory scheduled
by Santen (which notification shall describe the subject matter of any such
meeting), shall permit Inspire to assist Santen in the preparation for any such
meeting and shall promptly advise Inspire in writing of the outcome of any such
meeting.

     4.5  Funding.

          (a) Except as otherwise expressly provided in this Agreement, each
Party shall bear the entire cost and expense it incurs in connection with
fulfillment of its obligations under this Section 4.

          (b) Inspire shall invoice Santen for, and Santen shall pay, the
Transfer Price for the Compound supplied by Inspire pursuant to Section 4.3(c)
in accordance with Sections 6.2 and 7.

     4.6 Liability. Santen shall be responsible for, and hereby assumes, any
and all risks of personal injury or property damage attributable to the
negligent or willful acts or omissions, during the term of the Development
Program, of Santen or its Affiliates, and their respective directors, officers,
employees and agents. Inspire shall be responsible for, and hereby assumes, any
and all risks of personal injury or property damage attributable to the
negligent or willful acts or omissions, during the term of the Development
Program, of Inspire or its Affiliates, and their respective directors, officers,
employees and agents.

     4.7 Termination. In the event that, following the review by the
Coordinating Committee and the Executive Officers pursuant to Section 3.2,
Inspire believes that Santen has not made reasonably sufficient progress in the
development and commercialization of the Product in any country in the Territory
in a manner consistent with its obligations under Section 4.1, Inspire may
submit the matter to arbitration in San Francisco, California, for arbitration
pursuant to then current commercial arbitration rules of the American
Arbitration Association, but otherwise pursuant to Section 14.13. If the
arbitrators (who shall take into account, among other things, the relative
potential economic cost vs. benefit of developing and commercializing the
Product in such country) determine that Santen has not made reasonably
sufficient progress, Inspire shall have the right to terminate this Agreement
with respect to all countries except Japan pursuant to pursuant to Section 12.2;
provided, however, that if the arbitrators determine that Santen has not made
sufficiently reasonable progress with respect to Japan, Inspire shall have the
right to terminate this Agreement int its entirety pursuant to Section 12.2.

5   GRANT OF RIGHTS; MARKETING.

     5.1 Development License . Inspire hereby grants to Santen, during the term
of the Development Program, the exclusive (except as to Inspire as necessary for
the purposes of this

                                      -12-
<PAGE>

Agreement), paid-up license, with the right to grant sublicenses in accordance
with the terms of this Agreement, under the Licensed Technology, to conduct the
Development Program.

     5.2 Commercialization License . Inspire hereby grants to Santen an
exclusive (even as to Inspire) license throughout the Territory, with the right
to grant sublicenses in accordance with the terms of this Agreement, under the
Licensed Technology, to develop, use, manufacture, register, market and sell
Products in the Field; provided, however, that nothing in this Section 5.2
grants Santen the right to manufacture the Compound used in the manufacture of
the Products. With respect to any Patents that may issue in Japan during the
term of this Agreement, a statement referencing the exclusive license granted to
Santen pursuant to this Section 5.2 shall be registered with the Japanese Patent
Office at Santen=s cost, as soon as is practically possible after the issuance
of the respective Patents. Inspire hereby agrees that it will execute such
documents and instruments as may be required to effect the registration of such
statement and otherwise cooperate with Santen in connection with the
registration of such statement with the Japanese Patent Office, and in other
counties where required or permitted by applicable law.

     5.3  Sublicensing.

          (a) Santen may grant sublicenses of the licenses granted to Santen
under Section 5.2 for purposes of an Affiliate's or Sublicensee's co-performance
with Santen of Santen's obligations under Section 5.5 in Japan. In addition,
solely in connection with the grant of such sublicenses, Santen shall have the
right to grant a sublicense of the licenses granted to Santen under Section 5.1
for purposes of an Affiliate's or Sublicensee's co-performance with Santen of
Santen's obligations under Section 4 in Japan.

          (b) Santen shall have the right to grant sublicenses of the licenses
granted to Santen under Section 5.2 for purposes of an Affiliate's or
Sublicensee's performance of Santen's obligations under Section 5.5 in all
countries in the Territory other than Japan. In addition, solely in connection
with the grant of such sublicenses, Santen shall have the right to grant a
sublicense of the licenses granted to Santen under Section 5.1 for purposes of
an Affiliate's or Sublicensee's performance of Santen's obligations under
Section 4 in all countries in the Territory other than Japan.

          (c) No sublicense granted by Santen pursuant to this Section 5.3 shall
be valid unless: (i) Santen shall submit all proposed sublicenses to Inspire for
approval, which approval shall not be unreasonably withheld; (ii) Santen shall
guarantee and be responsible for the making of all payments due, and the making
of any reports under this Agreement, with respect to sales of Product by its
Affiliates or Sublicensees and their compliance with all applicable terms of
this Agreement; and (iii) each Affiliate or Sublicensee agrees in writing to
maintain books and records and permit Inspire to review such books and records
pursuant to the relevant provisions, and to observe all other applicable terms,
of this Agreement. In addition, no sublicense granted by Santen pursuant to this
Section 5.3 of the licenses granted to Santen under Section 5.1 shall be valid
unless each such Affiliate or Sublicensee agrees in writing to maintain
scientific records and permit Inspire to inspect and copy such records and visit
such facilities pursuant to the relevant provisions of Section 4.2, and

                                      -13-
<PAGE>

to observe all other applicable terms, of this Agreement. Santen shall promptly
provide Inspire with notice of any sublicense granted pursuant to this Section
5.3, and provide a copy of the sublicense to Inspire upon its request.

          (d) Santen hereby unconditionally guarantees the performance of any of
its Affiliates and Sublicensees hereunder. In the event of a breach by such an
Affiliate or Sublicensee in the observance of applicable terms of this
Agreement, Inspire shall be entitled to proceed against either such Affiliate or
Sublicensee or directly against Santen, as Inspire may determine in its sole
discretion, to enforce this Agreement.

     5.4 Grantback Rights . Subject to the terms and conditions of this
Agreement, Santen hereby grants to Inspire an exclusive (except as to Santen),
paid-up license under any patents or know-how that embody or relate to
Inventions that are owned or controlled by Santen or its Affiliates and relate
specifically to the Compound and/or the Product and are not of general utility
(i.e., useful for purposes other than uses with the Compound and/or Product):
(i) to develop, make, have made, use, offer to sell, sell and have sold products
with applications outside the Field for all purposes worldwide (including,
without limitation, within the Territory), and (ii) to develop, make, have made,
use, offer to sell, sell and have sold Products with applications within the
Field for all purposes outside the Territory. The foregoing licenses shall
include the right to grant sublicenses.

     5.5 Marketing Obligations, Rights. Santen shall use all commercially
reasonable efforts to market the Product in the Territory. In connection
therewith, Santen shall dedicate resources to marketing the Product that are
consistent with the resources that Santen, at all relevant times, would dedicate
to products containing compounds that were generated from Santen's own research
efforts which Santen decided to develop commercially and market and that have
pricing, volume and marketing potentials similar to those of the Product.
Santen, either itself and/or by and through its Affiliates, Sublicensees and
distributors, as the case may be, shall be responsible for, and shall have the
exclusive right to engage in, all marketing, advertising, promotional, launch
and sales activities in connection with such efforts.

     5.6 Trademarks. Santen shall market the Product throughout the Territory
under a trademark or trademarks (collectively, the "Trademark") selected by
Santen. Except as otherwise expressly provided in this Agreement, Santen shall
own all right, title and interest in and to such Trademark.

     5.7  Adverse Reaction Reporting  .

          (a) Each Party shall record, evaluate, summarize and review all
adverse drug experiences associated with the Compound and the Product. In order
that each Party may be fully informed of the adverse drug experiences associated
therewith that are known to the other Party, each Party shall report:

                                      -14-
<PAGE>

               (i)  In the case of Inspire, to:

                    Inspire Pharmaceuticals, Inc.
                    4222 Emperor Boulevard, Suite 470
                    Durham, North Carolina  27703
                    USA
                    Attention:  JoAnn Gorden, Manager, Regulatory Affairs &
                                Project Management
                    Facsimile No.: (919) 941-9797
                    Telephone No.: (919) 941-9777 ext. 288

               (ii) In the case of Santen, to:

                    Santen Pharmaceutical Co., Ltd.
                    3-9-19 Shimoshinjo
                    Higashiyodogawa-ku
                    Osaka 533-8651
                    JAPAN
                    Attention:  Koji Yamamoto, Ph.D., Deputy General Manager
                    Facsimile No.: (06) 6321-5312
                    Telephone No.: (06) 6321-9987

all "adverse events," as defined by the then current ICH guidelines, involving
the Compound and/or the Product (all such reports, "AE Reports"). "Serious"
adverse events shall be reported to the other Party within four working days (if
the event is fatal or life-threatening) or ten working days (if otherwise) after
a Party's (a "reporting Party") becoming aware of such an event and shall either
be reported by facsimile or telephone. The reporting Party shall report on a
quarterly basis all other adverse events that are known to the reporting Party
through either the receipt of clinical study documentation or post-market
surveillance. In addition, the reporting Party shall report all known instances
of use of the Product during pregnancy. In any event, each Party shall promptly
notify the other of any complaint received by such Party in sufficient detail
and in sufficient time to allow the responsible Party to comply with any and all
regulatory requirements imposed upon it in any country in the Territory. Each
Party shall also advise the other of any regulatory developments (e.g., proposed
recalls, labeling and other registrational dossier changes, etc.) affecting the
Compound or the Product in any country in the Territory.

          (b) According to current ICH guidelines, an "adverse event" is any
untoward medical occurrence in a patient or clinical investigation subject
administered a pharmaceutical product, which occurrence does not necessarily
have to have a causal relationship with the treatment.

          (c) According to current ICH guidelines, a "serious" adverse event is
any adverse drug experience that, at any dose, results in any of the following
outcomes: death, a life-threatening (at the time of the event) condition,
inpatient hospitalization or prolongation of existing

                                      -15-
<PAGE>

hospitalization, persistent or significant disability or incapacity, or a
congenital anomaly or birth defect. Other important medical events not meeting
such criteria may be considered serious if, based on appropriate medical
judgment, the event jeopardized the subject and required medical intervention to
prevent any one or more of such outcomes.

          (d) The details of adverse reaction reporting during the development
stage and thereafter shall be stipulated in a separate agreement to be entered
into by the Parties in due course.

6.   MILESTONES AND ROYALTIES.

     6.1 Milestone Payments. As further consideration to Inspire for the
license and other rights granted to Santen under this Agreement, Santen shall
pay to Inspire the following milestone payments upon the first occurrence of
each event set forth below with respect to the Product:

          [CONFIDENTIAL TREATMENT REQUESTED].

Each of the payments required pursuant to this Section 6.1 shall be paid within
15 days after such milestone has been achieved.

     6.2 Transfer Price. The transfer price to Santen for Compound supplied by
Inspire under this Agreement shall be an amount equal to [CONFIDENTIAL TREATMENT
REQUESTED]; provided, however, that the maximum amount to be included in
Inspire's Cost of Compound for the manufacture and supply of Compound to Santen
following the First Commercial Sale shall be [CONFIDENTIAL TREATMENT REQUESTED].
Such maximum amount shall be adjusted, commencing on January 1, 2000 and on each
January 1 thereafter, to reflect the change in the Producer Price Index for
Pharmaceutical Manufacturers (or such other index as the Parties may agree upon
from time to time) in the country in which the Compound was manufactured during
the preceding calendar year. The transfer price

                                      -16-
<PAGE>

of Compound to Santen, as determined under this Section 6.2, shall be referred
to as the "Transfer Price."

     6.3 Royalty Payments. As further consideration to Inspire for the license
and other rights granted to Santen under this Agreement, during the term of this
Agreement, Santen shall pay to Inspire a royalty on Net Sales of the Product
commencing on the First Commercial Sale by Santen, its Affiliates or its
Sublicensees, on a country-by-country and Product-by-Product basis, in an amount
equal to: (i) [CONFIDENTIAL TREATMENT REQUESTED] of the aggregate Net Sales of
the Product by Santen, its Affiliates and its Sublicensees in Japan; and (ii)
[CONFIDENTIAL TREATMENT REQUESTED] of the aggregate Net Sales of the Product by
Santen, its Affiliates and its Sublicensees throughout the remainder of the
Territory.

     6.4 Reduction for Generic Competition. With respect to any country in the
Territory where a product that is a Generic Product is being marketed by a Third
Party or Parties, the royalties payable to Inspire under Section 6.3 with
respect to Net Sales of the Product in such country shall be reduced by
[CONFIDENTIAL TREATMENT REQUESTED], commencing with the calendar quarter during
which such product becomes a Generic Product in such country.

     6.5 Obligation to Pay Royalties. The obligation to pay royalties to
Inspire under this Section 6 is imposed only once with respect to the same unit
of Product regardless of the number of Patents or quantity of Know-how
pertaining thereto. There shall be no obligation to pay royalties to Inspire
under this Section 6 on sales of Product between Santen and its Affiliates and
Sublicensees, but in such instances the obligation to pay royalties shall arise
upon the sale by Santen or its Affiliates or Sublicensees to unrelated Third
Parties, such as end users and distributors. Payments due under this Section 6
shall be deemed to accrue when Product is shipped or billed, whichever event
shall first occur.

7    PAYMENTS AND REPORTS.

     7.1  Payments.

          (a) Inspire shall submit invoices to Santen for the Transfer Price of
Compound promptly after each shipment thereof. Payments shall be made by Santen
within 30 days after the invoice date.

          (b) Beginning with the calendar quarter in which the First Commercial
Sale is made in the Territory and for each calendar quarter thereafter, Santen
shall submit a statement, Product-by-Product and country-by-country, of the
amount of Net Sales during such quarter and the amount of royalties due on such
Net Sales. Each such statement shall be accompanied by the payment due and shall
be submitted quarterly within 60 days after the end of each calendar quarter.

     7.2  Mode of Payment.  All invoices submitted by Inspire shall be stated
in U.S. Dollars. Santen shall make all payments required under this Agreement as
directed by Inspire from time to

                                      -17-
<PAGE>

time, net of any out-of-pocket transfer costs or fees, in U.S. Dollars.  All
payments due shall be translated at the current applicable foreign exchange rate
quoted by Sanwa Bank, Ltd., or any other bank of equivalent size and stature
that becomes Santen's principal bank during the term of this Agreement, on the
day and time of remittance.

     7.3 Records Retention. Santen and its Affiliates and Sublicensees shall
keep complete and accurate records pertaining to the sale of Product, and
Inspire shall keep complete and accurate records pertaining to Inspire's Cost of
Compound, for a period of three calendar years after the year in which such
sales or costs occurred, and in sufficient detail to permit the other Party to
confirm the accuracy of the aggregate royalty and/or Transfer Price calculations
hereunder.

     7.4  Audit Request.

          (a) During the term of this Agreement and for a period of two years
thereafter, at the request and expense of Inspire, Santen and its Affiliates and
Sublicensees shall permit an independent, certified public accountant appointed
by Inspire and reasonably acceptable to Santen, at reasonable times and upon
reasonable notice, to examine such records as may be necessary to: (i) determine
the correctness of any report or payment made under this Agreement; or (ii)
obtain information as to the aggregate royalties payable for any calendar
quarter in the case of Santen's failure to report or pay pursuant to this
Agreement. Said accountant shall not disclose to Inspire any information other
than information relating to said reports, royalties, and payments. Results of
any such examination shall be made available to both Parties.

          (b) During the term of this Agreement and for a period of two years
thereafter, at the request and expense of Santen, Inspire shall permit an
independent, certified public accountant appointed by Santen and reasonably
acceptable to Inspire, at reasonable times and upon reasonable notice, to
examine those records as may be necessary to verify the aggregate Cost of
Compound incurred by Inspire for any period. Said accountant shall not disclose
to Santen any information other than information relating to said Cost of
Compound. Results of any such examination shall be made available to both
Parties.

     7.5  Cost of Audit.

          (a) Inspire shall bear the full cost of the performance of any audit
requested by Inspire except as hereinafter set forth. If, as a result of any
inspection of the books and records of Santen, its Affiliates or its
Sublicensees, it is shown that Santen's payments under this Agreement were less
than the amount which should have been paid, then Santen shall make all payments
required to be made to eliminate any discrepancy revealed by said inspection
within 30 days after Inspire's demand therefor. Furthermore, if the payments
made were less than 95% of the amount that should have been paid during the
period in question, Santen shall also reimburse Inspire for the reasonable costs
of such audit.

                                      -18-
<PAGE>

           (b) Santen shall bear the full cost of the performance of any audit
requested by Santen except as hereinafter set forth. If, as a result of any
inspection of the books and records of Inspire, it is shown that Inspire
overstated its Cost of Compound under this Agreement for any period, then Santen
shall be entitled to a credit in the amount necessary to eliminate any
discrepancy revealed by said inspection. Such credit may be applied against any
amount due and owing to Inspire pursuant to this Agreement (e.g., milestone
payments, royalties, Transfer Price, etc.). Furthermore, if the amounts for any
period were overstated by more than five percent, Inspire shall also reimburse
Santen for the reasonable costs of such audit.

     7.6  No Non-Monetary Consideration for Sales. Without the prior written
consent of Inspire, Santen, its Affiliates and its Sublicensees shall not accept
or solicit any non-monetary consideration of the sale of the Product other than
as would be reflected in Net Sales. The use by Santen, its Affiliates and its
Sublicensees of a commercially reasonable amount of Product for promotional
sampling shall not violate this Section 7.6.

     7.7  Taxes.

          (a) In the event that Santen is required to withhold any tax to the
tax or revenue authorities in any country in the Territory regarding any payment
to Inspire due to the laws of such country, such amount shall be deducted from
the payment to be made by Santen, and Santen shall promptly notify Inspire of
such withholding and, within a reasonable amount of time after making such
deduction, furnish Inspire with copies of any tax certificate or other
documentation evidencing such withholding. Each Party agrees to cooperate with
the other Party in claiming exemptions from such deductions or withholdings
under any agreement or treaty from time to time in effect.

          (b) If Inspire has the legal obligation to collect and/or pay any
sales, use, excise or value added taxes, the appropriate amount shall be added
to Santen's invoice and paid by Santen, unless Santen provides Inspire with a
valid tax exemption certificate authorized by the appropriate taxing authority.

8    MANUFACTURE AND SUPPLY.

     8.1  Supply; Processing of Finished Product.

          (a) Commencing on the commercial launch of the Product and thereafter
during the term of this Agreement, subject to the terms and conditions of this
Section 8, Inspire shall supply Santen with all of Santen's requirements for
Compound for commercial use in the Territory (which shall be deemed to include
all of the requirements of Santen's Affiliates and Sublicensees), and Santen
shall purchase from Inspire all of such requirements for Compound. Santen shall
place orders for the requirements of its Affiliates and Sublicensees, and either
have Inspire ship directly to such Affiliates or Sublicensees or to Santen for
its reshipment to such Affiliates and Sublicensees.

                                      -19-
<PAGE>

          (b) Santen (or its Affiliates or Sublicensees) shall be responsible
for processing the Compound manufactured and supplied by Inspire into Product in
finished form and for putting such Product in final packaged form, including,
without limitation, all product labeling and other package inserts and materials
required by the applicable Regulatory Authorities.

          (c) The Parties shall cooperate in good faith and shall establish the
Compound Specifications for this Agreement. The Parties acknowledge and agree
that Inspire has granted, and may continue to grant, Third Parties licenses to
develop and commercialize the Compound outside the Field in Japan. In order to
facilitate manufacture of the Compound and the Product, as the Parties deem
appropriate, the Parties shall cooperate in good faith with such Third Parties
to establish Compound Specifications and Manufacturing Standards for this
Agreement that conform to the extent practicable to the specifications and
standards applicable to Inspire's manufacture of the Compound and products
containing the Compound for such Third Parties, and Inspire shall use all
reasonable efforts to cause such Third Parties to do the same.

     8.2  Forecasts. Commencing 12 months prior to the anticipated commercial
launch of the Product in any country in the Territory, no later than 180 days
prior to the first day of each calendar quarter ("Q1"), Santen shall provide
Inspire with a non-binding (except with respect to Q1), good faith rolling
forecast of estimated quantities in kilograms and anticipated delivery schedules
for Compound for the following 12-month period (i.e., Q1 and the next three
calendar quarters ("Q2," "Q3" and "Q4," respectively)), by calendar quarters.
The quantity indicated for Q1 shall be considered a firm order, in accordance
with Section 8.3. Such forecasts shall be revised and updated quarterly,
including firm orders for the next succeeding quarter.

     8.3  Orders.

          (a) Together with each forecast provided under Section 8.2 (the
"Current Forecast"), Santen shall place its firm order on a quarterly basis with
Inspire, setting forth kilograms, delivery dates and shipping instructions with
respect to each shipment of Compound for delivery in Q1. Inspire shall accept
such orders from Santen, subject to the other terms and conditions of this
Agreement, to the extent such quantity of Compound is: (i) no more than the
least of: (A) the quantity thereof reflected in the Current Forecast for Q1; (B)
[CONFIDENTIAL TREATMENT REQUESTED] of the quantity thereof reflected for Q2 in
the forecast that next preceded the Current Forecast; and (C) [CONFIDENTIAL
TREATMENT REQUESTED] of the quantity thereof reflected for Q3 in the forecast
that next preceded the forecast referred to in clause (i)(B); and (ii) no less
than the greatest of: (A) the quantity thereof reflected in the Current Forecast
for Q1; (B) [CONFIDENTIAL TREATMENT REQUESTED] of the quantity thereof reflected
for Q2 in the forecast that next preceded the Current Forecast; and (C)
[CONFIDENTIAL TREATMENT REQUESTED] of the quantity thereof reflected for Q3 in
the forecast that next preceded the forecast referred to in clause (ii)(B).
Santen's orders shall be made pursuant to purchase orders which are in a form
mutually acceptable to the Parties, to the extent that such form is not
inconsistent with the terms of this Agreement.

          (b) Inspire shall not be obligated to accept orders for Q1 to the
extent the quantity of Compound ordered exceeds the foregoing limitations, but
shall use good faith efforts to fill such

                                      -20-
<PAGE>

orders for such excess quantities from available supplies. In the event that
Inspire, despite the use of good faith efforts, is unable to supply such excess
quantities to Santen, such inability to supply shall not constitute a breach of
Inspire's obligations under this Section 8 or an Inability to Supply (as defined
in Section 8.9). Inspire shall use all reasonable efforts to notify Santen
within 10 days after receipt of an order of Inspire's ability to fill any
amounts of such orders in excess of the quantities that Inspire is obligated to
supply. Santen shall use all reasonable efforts to notify Inspire as soon as
possible of an increase in Santen's requirements for Compound materially in
excess of the limits set forth in Section 8.3(a).

          (c) In the event that Santen submits orders for Compound with respect
to any Q1 for less than the minimum quantity of Compound that Santen is required
to purchase under this Section 8, Inspire nevertheless shall have the right to
supply and ship to Santen (in accordance with the shipping instructions most
recently supplied by Santen), and Santen shall have the obligation to purchase
and accept from Inspire, such minimum quantity of Compound. Santen shall use all
reasonable efforts to notify Inspire as soon as possible of a decrease in
Santen's requirements for Compound materially below the limits set forth in
Section 8.3(a). In the event of such a decrease, Inspire shall use all
reasonable efforts, but shall not be required, to reduce accordingly the orders
for Compound that Inspire has placed with its Third Party Manufacturers or to
allocate to other purchasers Compound that Santen would have purchased but for
such decrease.

          (d) By way of illustration, examples of the maximum quantities of
Compound that Inspire is required to supply, and the minimum quantities of
Compound that Santen is required to order (and that Inspire is entitled to
supply), are set forth on Exhibit D.

     8.4 Delivery. With respect to exact shipping dates, Inspire shall use all
reasonable commercial efforts to ship quantities of Compound that Inspire is
obligated to supply pursuant to Section 8.3 on the dates specified in Santen's
purchase orders submitted and accepted in accordance with Section 8.3. All
Compound delivered pursuant to the terms of this Agreement shall be suitably
packed in bulk containers for shipment by Inspire, marked for shipment to the
destination point indicated in Santen's purchase order. All Compound will be
delivered F.O.B. the shipping point designated by Inspire. The shipping
packaging used by Inspire shall be in accordance with good commercial practice
with respect to protection of the Compound during transportation.

     8.5  Conformity; Specifications; Quality Control.

          (a) All quantities of Compound supplied by Inspire pursuant to this
Section 8 will comply with the Compound Specifications and applicable
Manufacturing Standards and shall adhere to all applicable governmental laws and
regulations relating to the manufacture, sale and shipment of each shipment of
Compound at the time it is shipped by Inspire hereunder.

          (b) Santen shall have the right to change the Compound Specifications,
from time to time, to accommodate the demands or requests of any Regulatory
Authority in the Territory at any time during the term of this Agreement on not
less than 12 months' prior written notice to Inspire.

                                      -21-
<PAGE>

Inspire shall use reasonable commercial efforts to meet such changes. In
addition, other changes to the Compound Specifications shall be made only upon
the mutual consent of the Parties. Any costs or expenses incurred by Inspire in
connection with such changes shall be borne by Santen, and Inspire shall be
entitled to include such costs and expenses in invoices submitted to Santen
pursuant to Section 7.1(a), from time to time.

          (c) Inspire shall conduct, or cause to be conducted, quality control
testing of Compound prior to shipment, in accordance with the Compound
Specifications and applicable Manufacturing Standards as are in effect from time
to time and such other quality control testing procedures agreed to by the
Parties from time to time (collectively, the "Testing Methods"). Inspire or its
designee shall retain records pertaining to such testing. Each shipment of
Compound hereunder shall be accompanied by a certified quality control protocol
and certificate of analysis for each lot of Compound therein as well as such
customs and other documentation as is necessary or appropriate.

          (d) Santen shall have the right, at reasonable times and upon
reasonable notice, to inspect all facilities at which Compound is manufactured
pursuant to this Section 8 for compliance with cGMP.

     8.6  Acceptance/Rejection; Interim Replacement.

          (a) Santen may test or cause to be tested Compound supplied under this
Section 8 in accordance with Santen's customary procedures within 30 days
(subject to increase to 45 days if Inspire obtains the consent of the supplier)
of its receipt at Santen's plant or that of its designee. Santen or its designee
shall have the right to reject any shipment of Compound made to it under this
Agreement that does not meet the Compound Specifications and applicable
Manufacturing Standards when received by it at such destination when tested in
accordance with the Testing Methods. All claims by Santen of non- conforming
Compound shall be deemed waived unless made by Santen in writing and received by
Inspire within such 30-day period.

          (b) All claims of non-conforming Compound shall be accompanied by a
report of analysis (including a sample of the Compound from the batch analyzed)
of the allegedly non-conforming Compound that shall have been made by Santen or
its designee, using the Testing Methods. If, after its own analysis of such
sample, Inspire confirms such non-conformity, then Inspire shall replace such
shipment at its expense, including charges incurred by Santen for shipping
and/or storage, if applicable. If, after its own analysis, Inspire does not
confirm such non-conformity, the Parties shall agree to retest the shipment or
otherwise in good faith attempt to agree upon a settlement of the issue. In the
event that the Parties cannot resolve the issue, the Parties shall submit the
disputed Compound to an independent testing laboratory, to be agreed upon by the
Parties, for testing in accordance with the Testing Methods. Notwithstanding
Section 14.13, the findings of such laboratory shall be binding on the Parties,
absent manifest error. Expenses of such testing shall be borne by the Party
adversely affected by such findings. In the event that any such shipment or
batch thereof is ultimately agreed or found not to meet the Compound
Specifications

                                      -22-
<PAGE>

or Manufacturing Standards, Inspire agrees to replace such shipment at its
expense, including charges incurred by Santen for shipping and/or storage, if
applicable. Santen shall return any such rejected shipment to Inspire if so
instructed by Inspire, at Inspire's expense.

          (c) During the pendency of any dispute concerning the conformity of a
shipment of Compound to the Compound Specifications and applicable Manufacturing
Standards, Inspire shall replace the shipment under dispute, at the request of
Santen. Such replacement Compound shall be ordered in accordance with Section
8.3.

          (d) Notwithstanding any other provision of this Agreement, Santen
shall not be required to pay for any shipment of Compound that fails to meet the
Compound Specifications, but Santen shall be obligated to pay in full for any
rejected shipment of Compound that is subsequently determined to meet the
Compound Specifications. In the event that Santen pays for a shipment of
Compound and subsequently rejects such shipment in accordance with the terms of
this Agreement, Santen shall be entitled to a refund or credit equal to the
amount paid with respect to such rejected shipment. Any such refund or credit
shall be reflected in the statements submitted by Santen pursuant to Section
7.1(b).

     8.7  Third Party Manufacturers.

          (a) The Parties acknowledge and agree that Inspire shall satisfy its
supply obligations to Santen hereunder through arrangements with Third Parties
who are engaged to perform services or supply facilities or goods (including,
without limitation, Compound) in connection with the manufacture, testing and/or
packaging of the Compound (each, a "Third Party Manufacturer"). Inspire shall
ensure that all such services, facilities and goods comply with the applicable
Manufacturing Standards in effect from time to time.

          (b) Santen hereby acknowledges and agrees that it has approved
[CONFIDENTIAL TREATMENT REQUESTED] Corporation as a Third Party Manufacturer.

          (c) In the event that Inspire intends to make arrangements with any
other Third Party Manufacturer, Inspire shall notify Santen thereof. In the
event that Santen objects to a particular Third Party Manufacturer that Inspire
intends to use to satisfy its obligations under this Section 8 (which objection
shall not be unreasonably made), then Santen shall no longer be required to
purchase Compound from Inspire pursuant to this Section 8 and shall be entitled
to have Compound manufactured by a qualified Third Party of Santen's own
choosing, subject to Inspire's right to fulfill uncancellable orders for
Compound intended for Santen under this Section 8. In the event of any such
objection by Santen, Inspire hereby grants to Santen, and Santen hereby accepts,
a royalty-free license (a "Manufacturing License") under the Licensed Technology
necessary to make, have made, use and sell Compound for all of Santen's (and its
Affiliates' and Sublicensees') requirements in the Territory for use in
connection with the fulfillment of Santen's obligations under Section 5.5. Such
Manufacturing License shall be subject to all other terms and conditions of this
Agreement. In addition, Santen agrees not to exercise any of its rights under
such Manufacturing

                                      -23-
<PAGE>

License except to the extent expressly permitted in this Section 8.7(c). In such
event, Inspire shall: (i) provide to Santen copies of all documentation within
Inspire's possession and control that is reasonably necessary for Santen to have
manufactured Compound; and (ii) provide such technical assistance to Santen as
is reasonably necessary to enable Santen to have manufactured Compound in
accordance with the Compound Specifications and Manufacturing Standards.

          (d) Inspire acknowledges and agrees that such Third Party
Manufacturers shall be subject to Section 8.5(a) and that use of a Third Party
Manufacturer shall not relieve Inspire of its obligations under Section 8.5(a).

     8.8  Shortage of Supply.

          (a) Inspire shall notify Santen: (i) as promptly as possible, but in
no event more than 30 days after Inspire's receipt of a firm order from Santen
as provided in Section 8.3, or (ii) immediately upon becoming aware of an event
of force majeure under Section 13 or any other event that would render Inspire
unable to supply the quantity of Compound to Santen that Inspire is required to
supply hereunder, if Inspire is unable to supply such quantities of Compound. In
such event, Inspire shall implement all reasonable measures to remedy such
shortage.

          (b) In the event that Inspire is unable to supply both Santen's
requirements of Compound and Inspire's and Third Parties' requirements for other
products containing the Compound or the Compound, as the case may be, due to
force majeure or otherwise, Inspire shall allocate the Compound that Inspire has
in inventory and that Inspire is able to produce among the quantities of all
such products, so that Santen receives at least its proportionate share of such
available supplies, as determined from reasonable forecasts (taking into
consideration past sales and sales performance against forecast) for the Product
and for such other products.

     8.9  Inability to Supply; Election of Remedies.

          (a) In the event of any Inability to Supply (as defined herein) the
Compound, Santen may elect either: (i) to manufacture (or have manufactured)
pursuant to Section 8.10 such quantity of Compound for sale in the Territory
that Inspire fails to so supply; or (ii) to assume full responsibility for the
supply of all of Santen's requirements for Compound under this Agreement. In
either case, Inspire shall cooperate with Santen in taking all actions that the
Parties deem reasonably necessary in order to remedy such Inability to Supply.
In the case of clause (ii), Santen's right so to supply shall continue until
such time as Inspire provides Santen with three months' written notice of
Inspire's desire to resume manufacturing and reasonably demonstrates that
Inspire is able adequately to supply Santen's requirements for Compound. In
addition, Santen's right so to supply shall continue thereafter for any
remaining noncancellable period of any contract that Santen shall have entered
into with any Third Party Manufacturer for the supply of Compound.

          (b) For purposes of this Section 8.9, an "Inability to Supply" shall
mean Inspire's failure for any reason, including without limitation force
majeure reasons or otherwise, to supply

                                      -24-
<PAGE>

Santen with quantities of Compound meeting the Compound Specifications and
Manufacturing Standards: [CONFIDENTIAL TREATMENT REQUESTED].

          (c) The remedy provided in this Section 8.9 shall be Santen's sole
remedy for Inability to Supply unless such Inability to Supply results from a
material breach of Inspire's material obligations contained in this Section 8.
In the event, however, that such Inability to Supply results from a material
breach of Inspire's material obligations contained in this Section 8, the remedy
provided in this Section 8.9 shall be in addition to any other remedies
available to Santen at law or in equity.

     8.10 Right to Manufacture. In the event that Santen duly exercises the
option provided in Section 8.9(a), Inspire hereby grants to Santen, and Santen
hereby accepts, a royalty-free license (the "Manufacturing License") under the
Licensed Technology necessary to make, have made, use and sell Compound for such
of Santen's requirements therefor as Santen has elected pursuant clause (i) or
(ii) of Section 8.9(a) in the Territory for use in connection with the
fulfillment of Santen's obligations under Section 5.5. Such Manufacturing
License shall be subject to all other terms and conditions of this Agreement. In
addition, Santen agrees not to exercise any of its rights under the
Manufacturing License except to the extent expressly permitted in Section
8.9(a). In such event: (i) Inspire shall provide to Santen copies of all
documentation within Inspire's possession and control that is reasonably
necessary for Santen to manufacture (or have manufactured) Compound; (ii)
Inspire shall provide such technical assistance to Santen as is reasonably
necessary to enable Santen to manufacture (or have manufactured) Compound in
accordance with the Compound Specifications and Manufacturing Standards; (iii)
to the extent that Santen manufactures (or has manufactured) Compound pursuant
to the Manufacturing License, Santen shall be relieved of its obligation to
purchase from Inspire such quantities of Compound; and (iv) Inspire shall
reasonably cooperate with Santen to establish an alternative supply, including
locating qualified Third Party manufacturers and sources of materials.

9.   OWNERSHIP; PATENTS.

     9.1  Ownership.

          (a) Except as otherwise provided in Section 9.1(b) or (c), Inspire
shall retain all right, title and interest in and to the Patents and Know-how,
regardless of which Party prepares and prosecutes the applications associated
therewith, or maintains the patents, copyrights or other intellectual property
rights related thereto, subject to the license granted to Santen pursuant to
Section 5.2. Rights to Inventions made solely by employees of Inspire shall
belong to Inspire.

          (b)  Rights to Inventions made solely by employees of Santen shall
belong to Santen.

                                      -25-
<PAGE>

          (c) Rights to Inventions which were made jointly by employees of
Inspire and by employees of Santen shall belong jointly to Inspire and to
Santen. Such joint Inventions shall be subject to the Field and territorial
restrictions of this Agreement with respect to manufacture, use and sale of such
Inventions. The Parties shall be under no territorial or field restrictions with
respect to Joint Inventions outside of the Field, and shall have the right to
manufacture, have manufactured, use, sell, and offer to sell Joint Inventions
outside of the Field anywhere, and to license others to do so, without
accounting to each other.

     9.2  Patent Maintenance.

          (a) Inspire shall have full responsibility for, and shall control the
preparation and prosecution of, all patent applications and the maintenance of
all patents relating to the Licensed Technology (including the Patents)
throughout the Territory. In connection therewith, Inspire shall consult with
Santen in order to assure that all future filings with respect to the Patents
are made in a timely manner and identify the relevant countries in the
Territory, to the extent that Inspire can do so. Inspire shall pay all costs and
expenses of filing, prosecuting and maintaining the Patents and the patents
covering Inventions owned by Inspire in the Territory. Notwithstanding the
foregoing, Inspire shall not have the right to file patent applications or
maintain patents for Inventions solely owned by Santen, regardless of whether
such Inventions relate to the Licensed Technology.

          (b) Inspire shall select qualified independent patent counsel to file
and prosecute all patent applications pursuant to Section 9.2(a). Inspire shall
provide copies to Santen of any filings made to, and written communications
received from, any patent office relating, in whole or in part, to the Licensed
Claims.

          (c) Each Party agrees promptly to provide to the other Party a
complete written disclosure of any Invention made by such Party. Inspire shall
determine whether any Invention owned solely by Inspire or jointly by Inspire
and Santen is patentable and whether filing a patent application is economically
justifiable, and if so, shall proceed with the preparation and prosecution of a
patent application covering any such Invention. If Inspire elects not to file
patent applications for any Invention owned jointly by the Parties, Santen shall
have the right to file and prosecute patent applications for such Joint
Inventions in any country in which Inspire elects not to file for patent
protection. Santen shall determine whether any Invention owned solely by Santen
is patentable and whether filing a patent application is economically
justifiable, and if so, shall proceed with the preparation and prosecution of a
patent application covering any such Invention.

          (d) Inspire and Santen shall share all costs and expenses of filing,
prosecuting and maintaining patents covering Inventions owned jointly by Santen
and Inspire in the Territory. If either Party elects not to pay for: (i) the
filing of a patent application in the Territory on any such Patent or Invention
which the other Party reasonably believes is patentable, or (ii) the further
prosecution or maintenance of any such Patent or Invention in the Territory, or
(iii) the filing of any divisional or continuing patent application based on any
Patent or Invention in the Territory, such Party shall notify the other Party in
a timely manner and the other Party may do so at its own

                                      -26-
<PAGE>

expense. In such event, such patent or application in the Territory shall be
assigned by such Party to the other Party, all of such assigning Party's rights
in such patent or application in the Territory shall cease, and, in the case
where Santen is the assigning Party, the licenses granted to Santen under
Section 5 shall be deemed to cover such patent or application.

          (e) Each Party agrees to cooperate with the other Party to execute all
lawful papers and instruments, to make all rightful oaths and declarations and
to provide consultation and assistance as may be necessary in the preparation,
prosecution, maintenance and enforcement of all such patents and patent
applications.

     9.3  Patent Enforcement.

          (a) If either Party learns of an infringement, unauthorized use,
misappropriation or ownership claim or threatened infringement or other such
claim (any of the foregoing, an "infringement") by a Third Party with respect to
any Licensed Technology within the Territory, such Party shall promptly notify
the other Party and shall provide such other Party with available evidence of
such infringement.

          (b) Inspire shall have the first right, but not the duty, to institute
patent infringement actions against Third Parties based on any Licensed
Technology in the Territory. If Inspire (or its designee) does not secure actual
cessation of such infringement or institute an infringement proceeding against
an offending Third Party within 180 days of learning of such infringement,
Santen shall have the right, but not the duty, to institute such an action with
respect to any infringement by such Third Party. The costs and expenses of any
such action (including fees of attorneys and other professionals) shall be borne
by the Party instituting the action, or, if the Parties elect to cooperate in
instituting and maintaining such action, such costs and expenses shall be borne
by the Parties in such proportions as they may agree in writing. Each Party
shall execute all necessary and proper documents, take such actions as shall be
appropriate to allow the other Party to institute and prosecute such
infringement actions and shall otherwise cooperate in the institution and
prosecution of such actions (including, without limitation, consenting to being
named as a nominal party thereto). Any award paid by Third Parties as a result
of such an infringement action (whether by way of settlement or otherwise) shall
be applied first to reimburse both Parties for all costs and expenses incurred
by the Parties with respect to such action on a pro rata basis and, if after
such reimbursement any funds shall remain from such award, they shall be
allocated as follows: [CONFIDENTIAL TREATMENT REQUESTED].

                                      -27-
<PAGE>

     9.4  Infringement Action by Third Parties.

          (a) In the event of the institution or threatened institution of any
suit by a Third Party against Santen for patent infringement involving the sale,
distribution or marketing of the Product in the Territory where such
infringement claim is a result of the use of the Licensed Technology, Santen
shall promptly notify Inspire in writing of such suit. Unless otherwise covered
by Section 11.3(c), Santen shall have the right to defend such suit at its own
expense and shall be responsible for all damages incurred as a result thereof.
Inspire hereby agrees to assist and cooperate with Santen, at Santen's
reasonable request and expense, in the defense of such suit (including, without
limitation, consenting to being named as a nominal party thereto). During the
pendency of such action and thereafter, Santen shall continue to make all
payments due under this Agreement.

          (b) In the event that Santen incurs any liability to a Third Party for
royalties or other damages as the result of any such action as described in
Section 9.4(a), Santen shall be entitled to a credit against royalties due under
this Agreement in an amount equal to [CONFIDENTIAL TREATMENT REQUESTED] of
Santen's actual costs in defending any such action, and [CONFIDENTIAL TREATMENT
REQUESTED] of the royalties and other damages Santen pays such Third Party;
provided, however, that Santen shall not be entitled to take as a credit in any
period any amount in excess of [CONFIDENTIAL TREATMENT REQUESTED] of the
royalties otherwise due under this Agreement with respect to Net Sales in the
country in which such action takes place. Any credit under this Section which is
not applied in the period incurred as a result of the foregoing limitation may
be carried forward and applied to any subsequent period until the credit has
been fully applied.

          (c) Any award from such Third Party that arises as a result of such
action as described in Section 9.4(a) (whether by way of judgment, award,
decree, settlement or otherwise) shall be allocated as follows: (i) if Santen
finally prevails, such award shall be applied first to reimburse Santen for all
costs and expenses incurred by it with respect to such action and, if after such
reimbursement any funds shall remain from such award, [CONFIDENTIAL TREATMENT
REQUESTED].

10.  PUBLICATION; CONFIDENTIALITY.

     10.1 Notification . Both Parties recognize that each may wish to publish
the results of their work relating to the subject matter of this Agreement.
However, both Parties also recognize the importance of acquiring patent
protection. Consequently, subject to any applicable laws or regulations
obligating either Party to do otherwise, any proposed publication by either
Party shall comply with this Section 10.1. At least 30 days before a manuscript
is to be submitted to a

                                      -28-
<PAGE>

publisher, the publishing Party will provide the Coordinating Committee with a
copy of the manuscript (or an English translation thereof). If the publishing
Party wishes to make an oral presentation, it will provide the Coordinating
Committee with a copy of the abstract (if one is submitted) at least 30 days
before it is to be submitted. The publishing Party will also provide to the
Coordinating Committee a copy of the text of the presentation, including all
slides, posters, and any other visual aids, at least 30 days before the
presentation is made.

     10.2 Review . The Coordinating Committee will review the manuscript,
abstract, text or any other material provided under Section 10.1 to determine
whether patentable subject matter is disclosed. The Coordinating Committee will
notify the publishing Party within 30 days of receipt of the proposed
publication if the Coordinating Committee, in good faith, determines that
patentable subject matter is or may be disclosed, or if the Coordinating
Committee, in good faith, believes Confidential Information is or may be
disclosed. If it is determined by the Coordinating Committee that patent
applications should be filed, the publishing Party shall delay its publication
or presentation for a period not to exceed 90 days from the Coordinating
Committee's receipt of the proposed publication or presentation to allow time
for the filing of patent applications covering patentable subject matter. In the
event that the delay needed to complete the filing of any necessary patent
application will exceed the 90-day period, the Coordinating Committee will
discuss the need for obtaining an extension of the publication delay beyond the
90-day period. If it is determined in good faith by the Coordinating Committee
that Confidential Information or proprietary information is being disclosed, the
Parties will consult in good faith to arrive at an agreement on mutually
acceptable modifications to the proposed publication or presentation to avoid
such disclosure.

     10.3 Exclusions . Nothing in Sections 10.1 and 10.2 shall prevent either
Party: (i) in connection with efforts to secure financing at any time during the
term of this Agreement, from issuing statements as to achievements made, and the
status of the work being done by the Parties, under this Agreement, so long as
such statements do not jeopardize the ability to obtain patent protection on
Inventions or disclose non-public technical or scientific Confidential
Information; or (ii) from issuing statements that such Party determines to be
necessary to comply with applicable law (including the disclosure requirements
of the U.S. Securities and Exchange Commission, Nasdaq or any other stock
exchange on which securities issued by such Party are traded); provided,
however, that, to the extent practicable under the circumstances, such Party
shall provide the other Party with a copy of the proposed text of such
statements sufficiently in advance of the scheduled release thereof to afford
such other Party a reasonable opportunity to review and comment upon the
proposed text. In addition, the provisions of Section 10.1 and 10.2 shall not
apply to Inventions solely owned by Santen.

     10.4 Confidentiality; Exceptions . Except to the extent expressly
authorized by this Agreement or otherwise agreed in writing, the Parties agree
that, during the term of this Agreement and for five years thereafter, the
receiving Party, its Affiliates, its licensees and its sublicensees shall, and
shall ensure that their respective employees, officers and directors shall, keep
completely confidential and not publish or otherwise disclose and not use for
any purpose any information furnished to it or them by the other Party, its
Affiliates, its licensees or its sublicensees or developed

                                      -29-
<PAGE>

under or in connection with this Agreement, except to the extent that it can be
established by the receiving Party by competent proof that such information: (i)
was already known to the receiving Party, other than under an obligation of
confidentiality, at the time of disclosure by the other Party; (ii) was
generally available to the public or otherwise part of the public domain at the
time of its disclosure to the receiving Party; (iii) became generally available
to the public or was otherwise part of the public domain after its disclosure
and other than through any act or omission of the receiving Party in breach of
this Agreement; or (iv) was disclosed to the receiving Party, other than under
an obligation of confidentiality, by a Third Party who had no obligation to the
disclosing Party not to disclose such information to others (all such
information to which none of the foregoing exceptions applies, "Confidential
Information").

     10.5 Exceptions to Obligation. The restrictions contained in Section 10.4
shall not apply to Confidential Information that: (i) is submitted by the
recipient to governmental authorities to facilitate the issuance of
Registrations for the Product, provided that reasonable measures shall be taken
to assure confidential treatment of such information; (ii) is provided by the
recipient to Third Parties under confidentiality provisions at least as
stringent as those in this Agreement, for consulting, manufacturing development,
manufacturing, external testing, marketing trials and, with respect to Santen,
to Third Parties who are Sublicensees or other development/marketing partners of
Santen with respect to any of the subject matter of this Agreement; or (iii) is
otherwise required to be disclosed in compliance with applicable laws or
regulations or order by a court or other regulatory body having competent
jurisdiction; provided that if a Party is required to make any such disclosure
of the other Party's Confidential Information such Party will, except where
impracticable for necessary disclosures (for example, to physicians conducting
studies or to health authorities), give reasonable advance notice to the other
Party of such disclosure requirement and, except to the extent inappropriate in
the case of patent applications, will use its best efforts to secure
confidential treatment of such Confidential Information required to be
disclosed.

     10.6 Limitations on Use. Each Party shall use, and cause each of its
Affiliates, its licensees and its sublicensees to use, any Confidential
Information obtained by such Party from the other Party, its Affiliates, its
licensees or its sublicensees, pursuant to this Agreement or otherwise, solely
in connection with the activities or transactions contemplated hereby.

     10.7 Remedies. Each Party shall be entitled, in addition to any other right
or remedy it may have, at law or in equity, to an injunction, without the
posting of any bond or other security, enjoining or restraining the other Party,
its Affiliates, its licensees and/or its sublicensees from any violation or
threatened violation of this Section 10.

11.  RECALL; INDEMNIFICATION.

     11.1 Investigation; Recall. In the event that the Regulatory Authority in
any country in the Territory shall allege or prove that the Product does not
comply with applicable rules and regulations in such country, Santen shall
notify Inspire immediately and both Parties shall cooperate fully

                                      -30-
<PAGE>

regarding the investigation and disposition of any such matter. If Santen is
required or should deem it appropriate to recall the Product and such recall is
due to any negligence, recklessness or wrongful intentional acts or omissions
by, or strict liability of, or breach of representation and warranty by,
Inspire, then and in such event Inspire shall bear all reasonable direct costs
associated with such recall, including, without limitation, refund of the
selling price and the actual cost of conducting the recall in accordance with
the recall guidelines of the applicable Regulatory Authority. Otherwise, Santen
shall bear all costs and expenses associated with such recall.

     11.2 Indemnification by Santen. Santen shall indemnify, defend and hold
harmless Inspire and its Affiliates, and their respective directors, officers,
employees and agents, from and against any and all liabilities, damages, losses,
costs and expenses (including the reasonable fees of attorneys and other
professionals) arising out of or resulting from:

          (a) negligence, recklessness or wrongful intentional acts or omissions
of Santen, its Affiliates or its Sublicensees, if any, and their respective
directors, officers, employees and agents, in connection with the work performed
by Santen under the Development Program;

          (b) any warranty claims, Product recalls or any tort claims of
personal injury (including death) or property damage relating to or arising out
of any manufacture, use, distribution or sale of the Product by Santen, its
Affiliates or its Sublicensees (except for claims based solely on the Compound)
due to any negligence, recklessness or wrongful intentional acts or omissions
by, or strict liability of, Santen, its Affiliates or its Sublicensees, and
their respective directors, officers, employees and agents, except, in each
case, to the comparative extent such claim arose out of or resulted from the
negligence, recklessness or wrongful intentional acts or omissions of Inspire
and its Affiliates, and their respective directors, officers, employees and
agents; or

          (c)  any breach of any representation or warranty made by Santen under
Section 2.

     11.3 Indemnification by Inspire. Inspire shall indemnify, defend and hold
harmless Santen, its Affiliates, its Sublicensees and distributors, and their
respective directors, officers, employees and agents, from and against any and
all liabilities, damages, losses, costs and expenses (including the reasonable
fees of attorneys and other professionals) arising out of or resulting from:

          (a) negligence, recklessness or wrongful intentional acts or omissions
of Inspire or its Affiliates, and their respective directors, officers,
employees and agents, in connection with Inspire's fulfillment of its
obligations under Section 4;

          (b) any warranty claims, Product recalls or any tort claims of
personal injury (including death) or property damage relating to or arising out
of any manufacture, use, distribution or sale of any Compound by Inspire or its
Affiliates due to any negligence, recklessness or wrongful intentional acts or
omissions by, or strict liability of, Inspire or its Affiliates, and their
respective directors, officers, employees and agents, except, in each case, to
the comparative extent such claim

                                      -31-
<PAGE>

arose out of or resulted from the negligence, recklessness or wrongful
intentional acts or omissions of Santen, its Affiliates or its Sublicensees, and
their respective directors, officers, employees and agents; or

          (c)  any breach of any representation or warranty made by Inspire
under Section 2.

     11.4 Notice of Indemnification. In the event that any person (an
"indemnitee") entitled to indemnification under Section 11.2 or 11.3 is seeking
such indemnification, such indemnitee shall inform the indemnifying Party of the
claim as soon as reasonably practicable after such indemnitee receives notice of
such claim, shall permit the indemnifying Party to assume direction and control
of the defense of the claim (including the sole right to settle it at the sole
discretion of the indemnifying Party, provided that such settlement does not
impose any obligation on, or otherwise adversely affect, the indemnitee or the
other Party) and shall cooperate as requested (at the expense of the
indemnifying Party) in the defense of the claim.

     11.5 Complete Indemnification. As the Parties intend complete
indemnification, all costs and expenses incurred by an indemnitee in connection
with enforcement of Sections 11.2 and 11.3 shall also be reimbursed by the
indemnifying Party.

12.  TERM; TERMINATION.

     12.1 Term. This Agreement shall become effective as of the Effective Date
and, unless earlier terminated pursuant to the other provisions of this Section
12, shall expire as follows:

          (a) As to each Product in each country in the Territory, this
Agreement shall expire on the later of: (i) the 10th anniversary of the First
Commercial Sale of such Product in such country, or (ii) the date on which the
sale of such Product ceases to be covered by a Licensed Claim in such country.

          (b) This Agreement shall expire in its entirety upon the expiration of
this Agreement with respect to all Products in all countries in the Territory
pursuant to Section 12.1(a).

     12.2 Termination for Cause. Either Party (the "non-breaching Party") may,
without prejudice to any other remedies available to it at law or in equity,
terminate this Agreement (or a portion of this Agreement as provided in Section
4.7) in the event the other Party (the "breaching Party") shall have materially
breached or defaulted in the performance of any of its material obligations
hereunder, and such default shall have continued for 60 days after written
notice thereof was provided to the breaching party by the non-breaching party
(or, if such default cannot be cured within such 60-day period, if the breaching
party does not commence and diligently continue actions to cure such default
during such 60-day period). Any such termination shall become effective at the
end of such 60-day period unless the breaching party has cured any such breach
or default prior to

                                      -32-
<PAGE>

the expiration of such 60-day period (or, if such default cannot be cured within
such 60-day period, if the breaching party has commenced and diligently
continued actions to cure such default). The right of either Party to terminate
this Agreement, or a portion of this Agreement, as provided in this Section 12.2
shall not be affected in any way by such Party's waiver or failure to take
action with respect to any previous default.

     12.3  Effect of Expiration or Termination.

          (a) Following the expiration of the term of this Agreement with
respect to a Product in a country pursuant to Section 12.1(a):

           (i) Santen shall have a non-exclusive, royalty-free, perpetual right,
with the right to grant sublicenses, to continue to make, have made, market,
distribute and sell such Product in such country, and the non-exclusive,
perpetual and paid-up right to use the Licensed Technology in connection
therewith; and

           (ii) Inspire shall have the fully-paid non-exclusive right, with the
right to grant sublicenses, to continue to cross-reference and otherwise
exercise its rights as set forth in Section 4.4(d) under the Registration(s) and
other regulatory filings for such Product in such country.

          (b)  Following expiration of the term of this Agreement in its
entirety pursuant to Section 12.1(b):

           (i) Santen shall have a non-exclusive, royalty-free, perpetual right
to continue to make, have made, use, market, distribute and sell all Products in
all countries in the Territory, and the non-exclusive, perpetual and paid-up
right to use the Licensed Technology in connection therewith;

           (ii) Inspire shall have: (A) the fully-paid non-exclusive right to
continue to cross-reference and otherwise exercise its rights as set forth in
Section 4.4(d) under the Registrations and other regulatory filings for all
Products in all countries in the Territory; and (B) the fully-paid, non-
exclusive, perpetual right to continue to use patents or know-how that embody or
relate to the Inventions described in Section 5.4 solely for the purposes set
forth in Section 5.4;

          (c) If this Agreement is terminated with respect to a portion of the
Territory (the "Subject Portion") by Inspire pursuant to Sections 4.7 and 12.2,
in addition to any other remedies available to Inspire at law or in equity: (i)
Santen shall promptly transfer to Inspire copies of all data, reports, records
and materials in Santen's possession or control that relate, whether exclusively
or non-exclusively, to the Development Program in the Subject Portion and return
to Inspire all relevant records and materials in Santen's possession or control
that relate exclusively to the Subject Portion and contain Confidential
Information of Inspire (provided that Santen may keep one copy of such
Confidential Information of Inspire for archival purposes only); (ii) all
licenses granted by Inspire to Santen under Sections 5.1 and 5.2 shall terminate
with respect to the Subject Portion; (iii) Santen

                                      -33-
<PAGE>

shall transfer to Inspire, or shall cause its designee(s) under Section 4.4(b)
to transfer to Inspire, ownership of all INDs, Registration Applications,
Registrations and other regulatory filings made or filed for the Product in the
Subject Portion if permitted by applicable laws and regulations; and (iv) all
sublicenses granted by Santen under this Agreement with respect to the Subject
Territory shall terminate.

          (d) If this Agreement is terminated in its entirety by Inspire
pursuant to Section 12.2 by reason of a breach by Santen, in addition to any
other remedies available to Inspire at law or in equity: (i) Santen shall
promptly transfer to Inspire copies of all data, reports, records and materials
in Santen's possession or control that relate to the Development Program and
return to Inspire all relevant records and materials in Santen's possession or
control containing Confidential Information of Inspire (provided that Santen may
keep one copy of such Confidential Information of Inspire for archival purposes
only); (ii) all licenses granted by Inspire to Santen under Sections 5.1 and 5.2
shall terminate; (iii) Santen shall transfer to Inspire, or shall cause its
designee(s) under Section 4.4(b) to transfer to Inspire, ownership of all INDs,
Registration Applications, Registrations and other regulatory filings made or
filed for the Product if permitted by applicable laws and regulations; (iv)
Santen shall license, royalty-free, to Inspire all rights to use the Trademark
with respect to the Product in all countries throughout the Territory under
terms and conditions to be agreed upon between the Parties; and (v) all
sublicenses granted by Santen under this Agreement shall terminate. Furthermore,
Inspire shall have a fully-paid, non-exclusive, perpetual right to continue to
use patents or know-how that embody or relate to the Inventions described in
Section 5.4 solely for the purposes set forth in Section 5.4.

          (e) If this Agreement is terminated by Santen pursuant to Section 12.2
by reason of a breach or default by Inspire, in addition to any other remedies
available to Santen at law or in equity,: (i) the license granted to Inspire by
Santen under Section 5.4 shall terminate; (ii) Santen shall have an exclusive,
royalty-free, perpetual right, with the right to grant sublicenses, to continue
to make, have made, use, market, distribute, sell, manufacture and have
manufactured any Product in the Territory, and the exclusive, perpetual and
paid-up right, with the right to grant sublicenses, to use the Licensed
Technology in connection therewith. To that end, Santen may continue to hold and
use all data, reports, records and materials that relate to or are prepared in
the course of the Development Program, and may hold all INDs, NDAs, NDA
Approvals and other regulatory filings made or filed by Santen for the Product,
pursuant to this Agreement, and may in its sole discretion continue any
sublicenses granted by Santen under this Agreement; and (iii) in order to secure
the right of Santen in clause (ii) of this Section 12.3(e), Inspire hereby
grants Santen the Manufacturing License and will use all reasonable efforts to
enable Santen to manufacture, or have manufactured Compound, including working
with Santen to establish arrangements with the Third Party Manufacturers.

     12.4  Accrued Rights; Surviving Obligations.

          (a) Termination, relinquishment or expiration of this Agreement for
any reason shall be without prejudice to any rights that shall have accrued to
the benefit of either Party prior to

                                      -34-
<PAGE>

such termination, relinquishment or expiration. Such termination, relinquishment
or expiration shall not relieve either Party from obligations which are
expressly indicated to survive termination or expiration of this Agreement.

          (b) All of the Parties' rights and obligations under Sections 3.5,
4.2(g), 4.2(h), 4.5, 4.6, 5.3(d), 5.6, 5.7 (so long as Santen sells Product), 7,
8.5(a), 8.6, 9.1, 9.3 (solely with respect to actions commenced before the
effective date of termination of this Agreement), 9.4, 10.4, 10.5, 10.6, 10.7,
11, 12.3, 12.4, and 14 shall survive termination, relinquishment or expiration
of this Agreement.

13.  FORCE MAJEURE.

     13.1 Events of Force Majeure. Neither Party shall be held liable or
responsible to the other Party nor be deemed to be in default under, or in
breach of any provision of, this Agreement for failure or delay in fulfilling or
performing any obligation of this Agreement when such failure or delay is due to
force majeure, and without the fault or negligence of the Party so failing or
delaying. For purposes of this Agreement, force majeure is defined as causes
beyond the control of the Party, including, without limitation, acts of God;
acts, regulations, or laws of any government; war; civil commotion; destruction
of production facilities or materials by fire, flood, earthquake, explosion or
storm; labor disturbances; epidemic; and failure of public utilities or common
carriers. In such event Inspire or Santen, as the case may be, shall immediately
notify the other Party of such inability and of the period for which such
inability is expected to continue. The Party giving such notice shall thereupon
be excused from such of its obligations under this Agreement as it is thereby
disabled from performing for so long as it is so disabled and the 30 days
thereafter. To the extent possible, each Party shall use reasonable efforts to
minimize the duration of any force majeure.

14.  MISCELLANEOUS.

     14.1 Relationship of Parties. Nothing in this Agreement is intended or
shall be deemed to constitute a partnership, agency, employer-employee or joint
venture relationship between the Parties. No Party shall incur any debts or make
any commitments for the other, except to the extent, if at all, specifically
provided herein.

     14.2 Assignment . Neither Party shall be entitled to assign its rights
hereunder without the express written consent of the other Party hereto, except
that each Party may assign its rights and transfer its duties hereunder to any
assignee of all or substantially all of its business (or that portion thereof to
which this Agreement relates) or in the event of such Party's merger,
consolidation or involvement in a similar transaction. No assignment and
transfer shall be valid or effective unless done in accordance with this Section
14.2 and unless and until the assignee/transferee shall agree in writing to be
bound by the provisions of this Agreement.

                                      -35-
<PAGE>

     14.3 Books and Records . Any books and records to be maintained under this
Agreement by a Party or its Affiliates or Sublicensees shall be maintained in
accordance with generally accepted accounting principles, consistently applied.

     14.4 Further Actions . Each Party shall execute, acknowledge and deliver
such further instruments, and do all such other acts, as may be necessary or
appropriate in order to carry out the purposes and intent of this Agreement.

     14.5  Notice.

          (a) Any notice or request required or permitted to be given under or
in connection with this Agreement shall be deemed to have been sufficiently
given if in writing and personally delivered or sent by certified mail (return
receipt requested), facsimile transmission (receipt verified), or overnight
express courier service (signature required), prepaid, to the Party for which
such notice is intended, at the address set forth for such Party below:

              (i)   In the case of Inspire, to:

                    Inspire Pharmaceuticals, Inc.
                    4222 Emperor Boulevard, Suite 470
                    Durham, North Carolina  27703
                    USA
                    Attention: Christy Shaffer, Ph.D.
                    Facsimile No.:  (919) 941-9797

             (ii)   In the case of Santen, to:

                    Santen Pharmaceuticals Co., Ltd.
                    3-9-19 Shimoshinjo
                    Higashiyodogawa-ku
                    Osaka 533-8651
                    JAPAN
                    Attention: Ichiro Otokozawa, General Manager
                              Business Development Dept.
                    Facsimile No.: 06-6321-8400

or to such other address for such Party as it shall have specified by like
notice to the other Party, provided that notices of a change of address shall be
effective only upon receipt thereof. If delivered personally or by facsimile
transmission, the date of delivery shall be deemed to be the date on which such
notice or request was given. If sent by overnight express courier service, the
date of delivery shall be deemed to be the next business day after such notice
or request was deposited with such service. If sent by certified mail, the date
of delivery shall be deemed to be the third business day

                                      -36-
<PAGE>

after such notice or request was deposited with the U.S. or Japanese Postal
Service, as the case may be.

          (b) All correspondence, notices and other communications of any kind
whatsoever given between the Parties, including, without limitation, all data,
information and reports relating to the Development Program and all regulatory
filings, shall be promptly provided to the other Party in English, or as an
English translation thereof, as the case may be.

     14.6 Use of Name. Except as otherwise provided herein, neither Party shall
have any right, express or implied, to use in any manner the name or other
designation of the other Party or any other trade name or trademark of the other
Party (including, without limitation, the Trademark) for any purpose in
connection with the performance of this Agreement.

     14.7 Public Announcements. Except as permitted by Section 10.3, neither
Party shall make any public announcement concerning this Agreement or the
subject matter hereof without the prior written consent of the other Party,
which shall not be unreasonably withheld, provided that it shall not be
unreasonable for a Party to withhold consent with respect to any public
announcement containing any of such Party's Confidential Information.

     14.8 Waiver. A waiver by either Party of any of the terms and conditions
of this Agreement in any instance shall not be deemed or construed to be a
waiver of such term or condition for the future, or of any subsequent breach
hereof. All rights, remedies, undertakings, obligations and agreements contained
in this Agreement shall be cumulative and none of them shall be in limitation of
any other remedy, right, undertaking, obligation or agreement of either Party.

     14.9 Compliance with Law. Nothing in this Agreement shall be deemed to
permit a Party to export, reexport or otherwise transfer any Product sold under
this Agreement without compliance with applicable laws.

     14.10 Severability. When possible, each provision of this Agreement will
be interpreted in such manner as to be effective and valid under applicable law,
but if any provision of this Agreement is held to be prohibited by or invalid
under applicable law, such provision will be ineffective only to the extent of
such prohibition or invalidity, without invalidating the remainder of this
Agreement.

     14.11 Amendment. No amendment, modification or supplement of any provisions
of this Agreement shall be valid or effective unless made in writing and signed
by a duly authorized officer of each Party.

     14.12 Governing Law; English Original Controlling . This Agreement shall be
governed by and interpreted in accordance with the laws of the State of Delaware
without regard to conflicts of law principles; provided, however, that any
arbitration proceeding conducted pursuant to Section 14.13 shall be governed by
the Convention on the Recognition and Enforcement of Foreign Arbitral

                                      -37-
<PAGE>

Awards of June 10, 1958. The English original of this Agreement shall prevail
over any translation hereof.

     14.13  Arbitration.

          (a) Except as expressly otherwise provided in this Agreement, any
dispute arising out of or relating to any provisions of this Agreement shall be
finally settled by arbitration to be held in Raleigh-Durham, North Carolina, if
initiated by Santen, under the then current commercial arbitration rules of the
American Arbitration Association, or in Osaka, Japan, if initiated by Inspire,
under the commercial arbitration rules of the Japan Commercial Arbitration
Association. Such arbitration shall be conducted by three arbitrators appointed
according to said rules and in the English language. The Parties shall instruct
such arbitrators to render a determination of any such dispute within four
months after their appointment.

          (b) Any award rendered by the arbitrator shall be final and binding
upon the Parties. Judgment upon any award rendered may be entered in any court
having jurisdiction, or application may be made to such court for a judicial
acceptance of the award and an order of enforcement, as the case may be. Each
Party shall pay its own expenses of arbitration, and the expenses of the
arbitrators shall be equally shared unless the arbitrators assess as part of
their award all or any part of the arbitration expenses of one Party (including
reasonable attorneys' fees) against the other Party.

          (c) This Section 14.13 shall not prohibit a Party from seeking
injunctive relief from a court of competent jurisdiction in the event of a
breach or prospective breach of this Agreement by the other Party which would
cause irreparable harm to the first Party.

     14.14 Entire Agreement. This Agreement and the Stock Purchase Agreement and
the other documents and agreements executed in connection herewith and
therewith, together with the schedules and exhibits to any of the foregoing,
sets forth the entire agreement and understanding between the Parties as to the
subject matter hereof and merges all prior discussions and negotiations between
them, and neither of the Parties shall be bound by any conditions, definitions,
warranties, understandings or representations with respect to such subject
matter other than as expressly provided herein or as duly set forth on or
subsequent to the date hereof in writing and signed by a proper and duly
authorized officer or representative of the Party to be bound thereby.

     14.15 Parties in Interest. All of the terms and provisions of this
Agreement shall be binding upon, inure to the benefit of and be enforceable by
the Parties hereto and their respective permitted successors and assigns.

     14.16 Descriptive Headings. The descriptive headings of this Agreement are
for convenience only, and shall be of no force or effect in construing or
interpreting any of the provisions of this Agreement.

                                      -38-
<PAGE>

     14.17 Counterparts. This Agreement may be executed simultaneously in any
number of counterparts, any one of which need not contain the signature of more
than one Party but all such counterparts taken together shall constitute one and
the same agreement.

                                      * * *

     IN WITNESS WHEREOF, each of the Parties has caused this Agreement to be
executed by its duly authorized representative as of the day and year first
above written.

                                    INSPIRE PHARMACEUTICALS, INC.

                                    By:  /s/ David J. Drutz
                                       ------------------------------------
                                      David J. Drutz, M.D., Vice Chairman

                                    SANTEN PHARMACEUTICAL CO., LTD.

                                    By:  /s/ Takakazu Morita
                                       ------------------------------------
                                      Takakazu Morita, Chief Executive Officer
                                         and President

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00012-of-00352.parquet"}]]